{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T06:11:33Z","timestamp":1792131093509,"version":"4.4.0"},"reference-count":266,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T00:00:00Z","timestamp":1753056000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T00:00:00Z","timestamp":1753056000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001798","name":"Edith Cowan University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001798","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Neurobiol"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Alzheimer\u2019s disease (AD) is a neurodegenerative disease characterised by neuropathological hallmarks, including extracellular amyloid plaques and neurofibrillary tangles. The disease is clinically defined by cognitive dysfunction, including learning, memory deficits, and behavioural changes. With the rising global prevalence of AD, early diagnosis is critical for implementing effective interventions before irreversible neuronal damage occurs. Biomarkers correlating amyloid deposition, tau pathology, neuroinflammation, and neurodegeneration are currently being investigated using cerebrospinal fluid analysis and positron emission tomography imaging. These methods are invasive or costly, limiting their widespread clinical utility. Blood-based biomarkers offer a promising alternative due to accessibility, cost-effectiveness, and feasibility for large-scale screening. Among blood-based biomarkers, plasma glial fibrillary acidic protein (GFAP) levels have gained interest in identifying individuals at risk of AD at preclinical stages. However, significant challenges remain, including methodological inconsistencies, analytical variability, and the need for standardisation across immunoassay platforms to ensure the clinical applicability of plasma GFAP measurement in AD diagnosis. Additionally, the specificity of GFAP for AD needs further evaluation, as increased plasma levels are also observed in other diseases. Similar issues are found with p-tau 217, the blood biomarker candidate for AD that has received the most attention. This review summarises the role of GFAP in the neuropathology of AD, provides evidence on plasma GFAP as an early blood biomarker for AD and identifies key knowledge gaps that need to be addressed. Future advancements in assay development and large-scale longitudinal studies are essential to validate its diagnostic and prognostic potential for community-based AD screening.<\/jats:p>","DOI":"10.1007\/s12035-025-05219-3","type":"journal-article","created":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T09:22:16Z","timestamp":1753089736000},"page":"15576-15608","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["The Role of Glial Fibrillary Acidic Protein in the Neuropathology of Alzheimer\u2019s Disease and Its Potential as a Blood Biomarker for Early Diagnosis and Progression"],"prefix":"10.1007","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2263-4720","authenticated-orcid":false,"given":"Ekanayaka M. S.","family":"Bandara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1973-9628","authenticated-orcid":false,"given":"Prita R.","family":"Asih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6409-8022","authenticated-orcid":false,"given":"Steve","family":"Pedrini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6708-3718","authenticated-orcid":false,"given":"Eugene","family":"Hone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8364-7808","authenticated-orcid":false,"given":"Warnakulasuriya Mary Ann Dipika Bin","family":"Fernando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4828-9363","authenticated-orcid":false,"given":"Ralph N.","family":"Martins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,21]]},"reference":[{"key":"5219_CR1","volume-title":"Global status report on the public health response to dementia","author":"World Health Organization","year":"2021","unstructured":"World Health Organization (2021) Global status report on the public health response to dementia. World Health Organization, Geneva"},{"key":"5219_CR2","doi-asserted-by":"publisher","unstructured":"Merta\u015f B, Bo\u015fgelmez I (2025) The role of genetic, environmental, and dietary factors in Alzheimer\u2019s disease: a narrative review. Int J Mol Sci 26(3). https:\/\/doi.org\/10.3390\/ijms26031222","DOI":"10.3390\/ijms26031222"},{"key":"5219_CR3","doi-asserted-by":"publisher","DOI":"10.3389\/fnut.2023.1213223","volume":"10","author":"S Arora","year":"2023","unstructured":"Arora S, Santiago JA, Bernstein M, Potashkin JA (2023) Diet and lifestyle impact the development and progression of Alzheimer\u2019s dementia. Front Nutr 10:1213223. https:\/\/doi.org\/10.3389\/fnut.2023.1213223","journal-title":"Front Nutr"},{"issue":"4","key":"5219_CR4","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1001\/jamaneurol.2013.5847","volume":"71","author":"GS Bloom","year":"2014","unstructured":"Bloom GS (2014) Amyloid-\u03b2 and tau: the trigger and bullet in Alzheimer disease pathogenesis. JAMA Neurol 71(4):505\u2013508. https:\/\/doi.org\/10.1001\/jamaneurol.2013.5847","journal-title":"JAMA Neurol"},{"issue":"1","key":"5219_CR5","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a006189","volume":"1","author":"A Serrano-Pozo","year":"2011","unstructured":"Serrano-Pozo A, Frosch MP, Masliah E, Hyman BT (2011) Neuropathological alterations in Alzheimer disease. Cold Spring Harb Perspect Med 1(1):a006189. https:\/\/doi.org\/10.1101\/cshperspect.a006189","journal-title":"Cold Spring Harb Perspect Med"},{"key":"5219_CR6","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1111\/j.1749-6632.2000.tb05561.x","volume":"924","author":"JQ Trojanowski","year":"2000","unstructured":"Trojanowski JQ, Lee VM (2000) \u201cFatal attractions\u201d of proteins. A comprehensive hypothetical mechanism underlying Alzheimer\u2019s disease and other neurodegenerative disorders. Ann N Y Acad Sci 924:62\u201367. https:\/\/doi.org\/10.1111\/j.1749-6632.2000.tb05561.x","journal-title":"Ann N Y Acad Sci"},{"issue":"R1","key":"5219_CR7","doi-asserted-by":"publisher","first-page":"R12","DOI":"10.1093\/hmg\/ddq160","volume":"19","author":"L Crews","year":"2010","unstructured":"Crews L, Masliah E (2010) Molecular mechanisms of neurodegeneration in Alzheimer\u2019s disease. Hum Mol Genet 19(R1):R12-20. https:\/\/doi.org\/10.1093\/hmg\/ddq160","journal-title":"Hum Mol Genet"},{"key":"5219_CR8","doi-asserted-by":"publisher","first-page":"5541","DOI":"10.2147\/ijn.S200490","volume":"14","author":"S Tiwari","year":"2019","unstructured":"Tiwari S, Atluri V, Kaushik A, Yndart A, Nair M (2019) Alzheimer\u2019s disease: pathogenesis, diagnostics, and therapeutics. Int J Nanomedicine 14:5541\u20135554. https:\/\/doi.org\/10.2147\/ijn.S200490","journal-title":"Int J Nanomedicine"},{"key":"5219_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2020.117253","volume":"421","author":"V Bhatia","year":"2021","unstructured":"Bhatia V, Sharma S (2021) Role of mitochondrial dysfunction, oxidative stress and autophagy in progression of Alzheimer\u2019s disease. J Neurol Sci 421:117253. https:\/\/doi.org\/10.1016\/j.jns.2020.117253","journal-title":"J Neurol Sci"},{"issue":"7","key":"5219_CR10","doi-asserted-by":"publisher","first-page":"552","DOI":"10.2174\/1570159X18666200122122512","volume":"18","author":"H Birla","year":"2020","unstructured":"Birla H, Minocha T, Kumar G, Misra A, Singh SK (2020) Role of oxidative stress and metal toxicity in the progression of Alzheimer\u2019s disease. Curr Neuropharmacol 18(7):552\u2013562. https:\/\/doi.org\/10.2174\/1570159X18666200122122512","journal-title":"Curr Neuropharmacol"},{"issue":"2","key":"5219_CR11","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1007\/s40120-022-00338-8","volume":"11","author":"AA Tahami Monfared","year":"2022","unstructured":"Tahami Monfared AA, Byrnes MJ, White LA, Zhang Q (2022) Alzheimer\u2019s disease: epidemiology and clinical progression. Neurol Ther 11(2):553\u2013569. https:\/\/doi.org\/10.1007\/s40120-022-00338-8","journal-title":"Neurol Ther"},{"key":"5219_CR12","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.neuroscience.2014.09.061","volume":"302","author":"CH Latta","year":"2015","unstructured":"Latta CH, Brothers HM, Wilcock DM (2015) Neuroinflammation in Alzheimer\u2019s disease; a source of heterogeneity and target for personalized therapy. Neuroscience 302:103\u2013111. https:\/\/doi.org\/10.1016\/j.neuroscience.2014.09.061","journal-title":"Neuroscience"},{"key":"5219_CR13","doi-asserted-by":"publisher","unstructured":"Doody R (2017) Developing disease-modifying treatments in Alzheimer\u2019s disease - a perspective from Roche and Genentech. J Prev Alzheimers Dis 4(4):264\u2013272. https:\/\/doi.org\/10.14283\/jpad.2017.40","DOI":"10.14283\/jpad.2017.40"},{"issue":"1","key":"5219_CR14","doi-asserted-by":"publisher","first-page":"e12295","DOI":"10.1002\/trc2.12295","volume":"8","author":"J Cummings","year":"2022","unstructured":"Cummings J, Lee G, Nahed P et al (2022) Alzheimer\u2019s disease drug development pipeline: 2022. Alzheimer\u2019s Dement (N Y) 8(1):e12295. https:\/\/doi.org\/10.1002\/trc2.12295","journal-title":"Alzheimer's Dement (N Y)"},{"key":"5219_CR15","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/9343514","volume":"2022","author":"SA Beshir","year":"2022","unstructured":"Beshir SA, Aadithsoorya AM, Parveen A et al (2022) Aducanumab therapy to treat Alzheimer\u2019s disease: a narrative review. Int J Alzheimers Dis 2022:9343514. https:\/\/doi.org\/10.1155\/2022\/9343514","journal-title":"Int J Alzheimers Dis"},{"issue":"2","key":"5219_CR16","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1055\/s-0039-1678581","volume":"39","author":"A Atri","year":"2019","unstructured":"Atri A (2019) Current and future treatments in Alzheimer\u2019s disease. Semin Neurol 39(2):227\u2013240. https:\/\/doi.org\/10.1055\/s-0039-1678581","journal-title":"Semin Neurol"},{"issue":"4","key":"5219_CR17","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/s1474-4422(13)70044-9","volume":"12","author":"VL Villemagne","year":"2013","unstructured":"Villemagne VL, Burnham S, Bourgeat P et al (2013) Amyloid \u03b2 deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer\u2019s disease: a prospective cohort study. Lancet Neurol 12(4):357\u2013367. https:\/\/doi.org\/10.1016\/s1474-4422(13)70044-9","journal-title":"Lancet Neurol"},{"issue":"1","key":"5219_CR18","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/s1474-4422(09)70299-6","volume":"9","author":"CR Jack Jr","year":"2010","unstructured":"Jack CR Jr, Knopman DS, Jagust WJ et al (2010) Hypothetical model of dynamic biomarkers of the Alzheimer\u2019s pathological cascade. Lancet Neurol 9(1):119\u2013128. https:\/\/doi.org\/10.1016\/s1474-4422(09)70299-6","journal-title":"Lancet Neurol"},{"issue":"8","key":"5219_CR19","doi-asserted-by":"publisher","first-page":"5143","DOI":"10.1002\/alz.13859","volume":"20","author":"CR Jack Jr","year":"2024","unstructured":"Jack CR Jr, Andrews JS, Beach TG et al (2024) Revised criteria for diagnosis and staging of Alzheimer\u2019s disease: Alzheimer\u2019s association workgroup. Alzheimers Dement 20(8):5143\u20135169. https:\/\/doi.org\/10.1002\/alz.13859","journal-title":"Alzheimers Dement"},{"issue":"6","key":"5219_CR20","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1038\/s41591-021-01382-x","volume":"27","author":"O Hansson","year":"2021","unstructured":"Hansson O (2021) Biomarkers for neurodegenerative diseases. Nat Med 27(6):954\u2013963. https:\/\/doi.org\/10.1038\/s41591-021-01382-x","journal-title":"Nat Med"},{"key":"5219_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2021.101492","volume":"72","author":"L Feng","year":"2021","unstructured":"Feng L, Li J, Zhang R (2021) Current research status of blood biomarkers in Alzheimer\u2019s disease: diagnosis and prognosis. Ageing Res Rev 72:101492. https:\/\/doi.org\/10.1016\/j.arr.2021.101492","journal-title":"Ageing Res Rev"},{"issue":"1","key":"5219_CR22","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/s41398-020-01137-1","volume":"11","author":"P Chatterjee","year":"2021","unstructured":"Chatterjee P, Pedrini S, Stoops E et al (2021) Plasma glial fibrillary acidic protein is elevated in cognitively normal older adults at risk of Alzheimer\u2019s disease. Transl Psychiatry 11(1):27. https:\/\/doi.org\/10.1038\/s41398-020-01137-1","journal-title":"Transl Psychiatry"},{"issue":"1","key":"5219_CR23","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1152\/physrev.00042.2016","volume":"98","author":"A Verkhratsky","year":"2018","unstructured":"Verkhratsky A, Nedergaard M (2018) Physiology of Astroglia. Physiol Rev 98(1):239\u2013389. https:\/\/doi.org\/10.1152\/physrev.00042.2016","journal-title":"Physiol Rev"},{"issue":"1","key":"5219_CR24","doi-asserted-by":"publisher","DOI":"10.1186\/2045-8118-9-23","volume":"9","author":"A-C Luissint","year":"2012","unstructured":"Luissint A-C, Artus C, Glacial F, Ganeshamoorthy K, Couraud P-O (2012) Tight junctions at the blood brain barrier: physiological architecture and disease-associated dysregulation. Fluids Barriers CNS 9(1):23. https:\/\/doi.org\/10.1186\/2045-8118-9-23","journal-title":"Fluids Barriers CNS"},{"issue":"46","key":"5219_CR25","doi-asserted-by":"publisher","first-page":"17513","DOI":"10.1073\/pnas.0602841103","volume":"103","author":"U Wilhelmsson","year":"2006","unstructured":"Wilhelmsson U, Bushong EA, Price DL et al (2006) Redefining the concept of reactive astrocytes as cells that remain within their unique domains upon reaction to injury. Proc Nat Acad Sci 103(46):17513\u201317518. https:\/\/doi.org\/10.1073\/pnas.0602841103","journal-title":"Proc Nat Acad Sci"},{"key":"5219_CR26","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2018.00625","volume":"9","author":"P Edison","year":"2018","unstructured":"Edison P, Donat CK, Sastre M (2018) In vivo imaging of glial activation in Alzheimer\u2019s disease. Front Neurol 9:625. https:\/\/doi.org\/10.3389\/fneur.2018.00625","journal-title":"Front Neurol"},{"issue":"4","key":"5219_CR27","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.jalz.2019.09.004","volume":"16","author":"FM Elahi","year":"2020","unstructured":"Elahi FM, Casaletto KB, La Joie R et al (2020) Plasma biomarkers of astrocytic and neuronal dysfunction in early- and late-onset Alzheimer\u2019s disease. Alzheimers Dement 16(4):681\u2013695. https:\/\/doi.org\/10.1016\/j.jalz.2019.09.004","journal-title":"Alzheimers Dement"},{"issue":"2","key":"5219_CR28","doi-asserted-by":"publisher","first-page":"e87","DOI":"10.1016\/S2666-7568(20)30061-1","volume":"2","author":"IMW Verberk","year":"2021","unstructured":"Verberk IMW, Laarhuis MB, van den Bosch KA et al (2021) Serum markers glial fibrillary acidic protein and neurofilament light for prognosis and monitoring in cognitively normal older people: a prospective memory clinic-based cohort study. The Lancet healthy longevity 2(2):e87\u2013e95. https:\/\/doi.org\/10.1016\/S2666-7568(20)30061-1","journal-title":"Lancet Health Longev"},{"issue":"1","key":"5219_CR29","doi-asserted-by":"publisher","DOI":"10.1002\/dad2.12291","volume":"14","author":"D Shir","year":"2022","unstructured":"Shir D, Graff-Radford J, Hofrenning EI et al (2022) Association of plasma glial fibrillary acidic protein (GFAP) with neuroimaging of Alzheimer\u2019s disease and vascular pathology. Alzheimers Dement (Amst) 14(1):e12291. https:\/\/doi.org\/10.1002\/dad2.12291","journal-title":"Alzheimers Dement (Amst)"},{"issue":"1","key":"5219_CR30","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1002\/alz.12614","volume":"19","author":"H Stocker","year":"2023","unstructured":"Stocker H, Beyer L, Perna L et al (2023) Association of plasma biomarkers, p-tau181, glial fibrillary acidic protein, and neurofilament light, with intermediate and long-term clinical Alzheimer\u2019s disease risk: results from a prospective cohort followed over 17 years. Alzheimer\u2019s Dement 19(1):25\u201335. https:\/\/doi.org\/10.1002\/alz.12614","journal-title":"Alzheimer's Dement"},{"issue":"1","key":"5219_CR31","doi-asserted-by":"publisher","DOI":"10.1002\/dad2.12298","volume":"14","author":"MM Gonzales","year":"2022","unstructured":"Gonzales MM, Wang CP, Short MI et al (2022) Blood biomarkers for cognitive decline and clinical progression in a Mexican American cohort. Alzheimers Dement (Amst) 14(1):e12298. https:\/\/doi.org\/10.1002\/dad2.12298","journal-title":"Alzheimers Dement (Amst)"},{"issue":"6","key":"5219_CR32","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1002\/alz.12447","volume":"18","author":"P Chatterjee","year":"2022","unstructured":"Chatterjee P, Pedrini S, Ashton NJ et al (2022) Diagnostic and prognostic plasma biomarkers for preclinical Alzheimer\u2019s disease. Alzheimers Dement 18(6):1141\u20131154. https:\/\/doi.org\/10.1002\/alz.12447","journal-title":"Alzheimers Dement"},{"issue":"4","key":"5219_CR33","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1002\/alz.12724","volume":"19","author":"P Chatterjee","year":"2023","unstructured":"Chatterjee P, Pedrini S, Doecke JD et al (2023) Plasma A\u03b242\/40 ratio, p-tau181, GFAP, and NfL across the Alzheimer\u2019s disease continuum: a cross-sectional and longitudinal study in the AIBL cohort. Alzheimers Dement 19(4):1117\u20131134. https:\/\/doi.org\/10.1002\/alz.12724","journal-title":"Alzheimers Dement"},{"issue":"1","key":"5219_CR34","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s13024-019-0333-5","volume":"14","author":"MA DeTure","year":"2019","unstructured":"DeTure MA, Dickson DW (2019) The neuropathological diagnosis of Alzheimer\u2019s disease. Mol Neurodegener 14(1):32. https:\/\/doi.org\/10.1186\/s13024-019-0333-5","journal-title":"Mol Neurodegener"},{"issue":"3","key":"5219_CR35","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/s1474-4422(18)30028-0","volume":"17","author":"BA Gordon","year":"2018","unstructured":"Gordon BA, Blazey TM, Su Y et al (2018) Spatial patterns of neuroimaging biomarker change in individuals from families with autosomal dominant Alzheimer\u2019s disease: a longitudinal study. Lancet Neurol 17(3):241\u2013250. https:\/\/doi.org\/10.1016\/s1474-4422(18)30028-0","journal-title":"Lancet Neurol"},{"issue":"6","key":"5219_CR36","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1016\/j.mayocp.2017.02.011","volume":"92","author":"RJ Caselli","year":"2017","unstructured":"Caselli RJ, Beach TG, Knopman DS, Graff-Radford NR (2017) Alzheimer disease: scientific breakthroughs and translational challenges. Mayo Clin Proc 92(6):978\u2013994. https:\/\/doi.org\/10.1016\/j.mayocp.2017.02.011","journal-title":"Mayo Clin Proc"},{"issue":"9","key":"5219_CR37","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1056\/NEJMoa1202753","volume":"367","author":"RJ Bateman","year":"2012","unstructured":"Bateman RJ, Xiong C, Benzinger TLS et al (2012) Clinical and biomarker changes in dominantly inherited Alzheimer\u2019s disease. N Engl J Med 367(9):795\u2013804. https:\/\/doi.org\/10.1056\/NEJMoa1202753","journal-title":"N Engl J Med"},{"issue":"1","key":"5219_CR38","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s13195-017-0283-5","volume":"9","author":"PS Aisen","year":"2017","unstructured":"Aisen PS, Cummings J, Jack CR et al (2017) On the path to 2025: understanding the Alzheimer\u2019s disease continuum. Alzheimer\u2019s Res Ther 9(1):60. https:\/\/doi.org\/10.1186\/s13195-017-0283-5","journal-title":"Alzheimer's Res Ther"},{"issue":"1","key":"5219_CR39","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s13195-017-0297-z","volume":"9","author":"M Crous-Bou","year":"2017","unstructured":"Crous-Bou M, Minguill\u00f3n C, Gramunt N, Molinuevo JL (2017) Alzheimer\u2019s disease prevention: from risk factors to early intervention. Alzheimers Res Ther 9(1):71. https:\/\/doi.org\/10.1186\/s13195-017-0297-z","journal-title":"Alzheimers Res Ther"},{"issue":"19","key":"5219_CR40","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1001\/jama.2015.4668","volume":"313","author":"WJ Jansen","year":"2015","unstructured":"Jansen WJ, Ossenkoppele R, Knol DL et al (2015) Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. JAMA 313(19):1924\u20131938. https:\/\/doi.org\/10.1001\/jama.2015.4668","journal-title":"JAMA"},{"issue":"3","key":"5219_CR41","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.jalz.2019.01.010","volume":"15","author":"Alzheimer\u2019s Association","year":"2019","unstructured":"Alzheimer\u2019s Association (2019) 2019 Alzheimer\u2019s disease facts and figures. Alzheimer\u2019s Dement 15(3):321\u2013387. https:\/\/doi.org\/10.1016\/j.jalz.2019.01.010","journal-title":"Alzheimer's Dement"},{"issue":"3","key":"5219_CR42","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","volume":"7","author":"GM McKhann","year":"2011","unstructured":"McKhann GM, Knopman DS, Chertkow H et al (2011) The diagnosis of dementia due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement 7(3):263\u2013269. https:\/\/doi.org\/10.1016\/j.jalz.2011.03.005","journal-title":"Alzheimers Dement"},{"issue":"3","key":"5219_CR43","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.jalz.2011.03.004","volume":"7","author":"CR Jack Jr","year":"2011","unstructured":"Jack CR Jr, Albert MS, Knopman DS et al (2011) Introduction to the recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimer\u2019s Dement 7(3):257\u2013262. https:\/\/doi.org\/10.1016\/j.jalz.2011.03.004","journal-title":"Alzheimer's Dement"},{"issue":"8","key":"5219_CR44","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1016\/S1474-4422(07)70178-3","volume":"6","author":"B Dubois","year":"2007","unstructured":"Dubois B, Feldman HH, Jacova C et al (2007) Research criteria for the diagnosis of Alzheimer\u2019s disease: revising the NINCDS\u2013ADRDA criteria. Lancet Neurol 6(8):734\u2013746. https:\/\/doi.org\/10.1016\/S1474-4422(07)70178-3","journal-title":"Lancet Neurol"},{"issue":"11","key":"5219_CR45","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1016\/S1474-4422(10)70223-4","volume":"9","author":"B Dubois","year":"2010","unstructured":"Dubois B, Feldman HH, Jacova C et al (2010) Revising the definition of Alzheimer\u2019s disease: a new lexicon. Lancet Neurol 9(11):1118\u20131127. https:\/\/doi.org\/10.1016\/S1474-4422(10)70223-4","journal-title":"Lancet Neurol"},{"key":"5219_CR46","doi-asserted-by":"publisher","unstructured":"First MB (2013) Diagnostic and statistical manual of mental disorders, 5th edition, and clinical utility. J Nerv Ment Dis 201(9):727\u2013729. https:\/\/doi.org\/10.1097\/NMD.0b013e3182a2168a","DOI":"10.1097\/NMD.0b013e3182a2168a"},{"issue":"1","key":"5219_CR47","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1186\/s12877-021-02471-9","volume":"21","author":"Y Su","year":"2021","unstructured":"Su Y, Dong J, Sun J et al (2021) Cognitive function assessed by mini-mental state examination and risk of all-cause mortality: a community-based prospective cohort study. BMC Geriatr 21(1):524. https:\/\/doi.org\/10.1186\/s12877-021-02471-9","journal-title":"BMC Geriatr"},{"issue":"1","key":"5219_CR48","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1080\/13803395.2010.493149","volume":"33","author":"DL Woods","year":"2011","unstructured":"Woods DL, Kishiyamaa MM, Lund EW et al (2011) Improving digit span assessment of short-term verbal memory. J Clin Exp Neuropsychol 33(1):101\u2013111. https:\/\/doi.org\/10.1080\/13803395.2010.493149","journal-title":"J Clin Exp Neuropsychol"},{"issue":"11","key":"5219_CR49","doi-asserted-by":"publisher","first-page":"793","DOI":"10.30773\/pi.2019.0061","volume":"16","author":"YD Ahn","year":"2019","unstructured":"Ahn YD, Yi D, Joung H et al (2019) Normative data for the logical memory subtest of the wechsler memory scale-IV in middle-aged and elderly Korean people. Psychiatry Investig 16(11):793\u2013799. https:\/\/doi.org\/10.30773\/pi.2019.0061","journal-title":"Psychiatry Investig"},{"issue":"4","key":"5219_CR50","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1111\/j.1532-5415.2005.53221.x","volume":"53","author":"ZS Nasreddine","year":"2005","unstructured":"Nasreddine ZS, Phillips NA, B\u00e9dirian V et al (2005) The Montreal cognitive assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc 53(4):695\u2013699. https:\/\/doi.org\/10.1111\/j.1532-5415.2005.53221.x","journal-title":"J Am Geriatr Soc"},{"issue":"2","key":"5219_CR51","doi-asserted-by":"publisher","first-page":"357","DOI":"10.3390\/neurolint14020029","volume":"14","author":"C Fornari","year":"2022","unstructured":"Fornari C, Mori F, Zoppi N et al (2022) Diagnostic accuracy of the five-word test for mild cognitive impairment due to Alzheimer\u2019s disease. Neurol Int 14(2):357\u2013367. https:\/\/doi.org\/10.3390\/neurolint14020029","journal-title":"Neurol Int"},{"issue":"5","key":"5219_CR52","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1212\/WNL.0000000000002923","volume":"87","author":"CR Jack Jr","year":"2016","unstructured":"Jack CR Jr, Bennett DA, Blennow K et al (2016) A\/T\/N: an unbiased descriptive classification scheme for Alzheimer disease biomarkers. Neurology 87(5):539\u2013547. https:\/\/doi.org\/10.1212\/WNL.0000000000002923","journal-title":"Neurology"},{"issue":"4","key":"5219_CR53","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a006213","volume":"2","author":"KA Johnson","year":"2012","unstructured":"Johnson KA, Fox NC, Sperling RA, Klunk WE (2012) Brain imaging in Alzheimer disease. Cold Spring Harb Perspect Med 2(4):a006213. https:\/\/doi.org\/10.1101\/cshperspect.a006213","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"6","key":"5219_CR54","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1053\/j.sult.2020.08.011","volume":"41","author":"PA Rowley","year":"2020","unstructured":"Rowley PA, Samsonov AA, Betthauser TJ et al (2020) Amyloid and tau PET imaging of Alzheimer disease and other neurodegenerative conditions. Semin Ultrasound CT MR 41(6):572\u2013583. https:\/\/doi.org\/10.1053\/j.sult.2020.08.011","journal-title":"Semin Ultrasound CT MR"},{"issue":"2","key":"5219_CR55","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1373\/clinchem.2009.130518","volume":"56","author":"C Mulder","year":"2010","unstructured":"Mulder C, Verwey NA, van der Flier WM et al (2010) Amyloid-\u03b2(1\u201342), total tau, and phosphorylated tau as cerebrospinal fluid biomarkers for the diagnosis of Alzheimer disease. Clin Chem 56(2):248\u2013253. https:\/\/doi.org\/10.1373\/clinchem.2009.130518","journal-title":"Clin Chem"},{"issue":"1","key":"5219_CR56","doi-asserted-by":"publisher","DOI":"10.1002\/dad2.12314","volume":"14","author":"FH Bouwman","year":"2022","unstructured":"Bouwman FH, Frisoni GB, Johnson SC et al (2022) Clinical application of CSF biomarkers for Alzheimer\u2019s disease: from rationale to ratios. Alzheimers Dement (Amst) 14(1):e12314. https:\/\/doi.org\/10.1002\/dad2.12314","journal-title":"Alzheimers Dement (Amst)"},{"issue":"4","key":"5219_CR57","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","volume":"14","author":"CR Jack Jr","year":"2018","unstructured":"Jack CR Jr, Bennett DA, Blennow K et al (2018) NIA-AA research framework: toward a biological definition of Alzheimer\u2019s disease. Alzheimers Dement 14(4):535\u2013562. https:\/\/doi.org\/10.1016\/j.jalz.2018.02.018","journal-title":"Alzheimers Dement"},{"key":"5219_CR58","doi-asserted-by":"publisher","unstructured":"The Ronald and Nancy Reagan Research Institute of the Alzheimer\u2019s Association and the National Institute on Aging Working Group (1998) Consensus report of the working group on: \u201cmolecular and biochemical markers of Alzheimer\u2019s disease.\u201d Neurobiol Aging 19(2):109\u2013116. https:\/\/doi.org\/10.1016\/S0197-4580(98)00022-0","DOI":"10.1016\/S0197-4580(98)00022-0"},{"issue":"6","key":"5219_CR59","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1111\/joim.12816","volume":"284","author":"K Blennow","year":"2018","unstructured":"Blennow K, Zetterberg H (2018) Biomarkers for Alzheimer\u2019s disease: current status and prospects for the future. J Intern Med 284(6):643\u2013663. https:\/\/doi.org\/10.1111\/joim.12816","journal-title":"J Intern Med"},{"key":"5219_CR60","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/bs.acc.2022.09.006","volume":"112","author":"J Simr\u00e9n","year":"2023","unstructured":"Simr\u00e9n J, Elmgren A, Blennow K, Zetterberg H (2023) Chapter six - fluid biomarkers in Alzheimer\u2019s disease. Adv Clin Chem 112:249\u2013281. https:\/\/doi.org\/10.1016\/bs.acc.2022.09.006","journal-title":"Adv Clin Chem"},{"issue":"5","key":"5219_CR61","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1038\/s43587-023-00403-3","volume":"3","author":"O Hansson","year":"2023","unstructured":"Hansson O, Blennow K, Zetterberg H, Dage J (2023) Blood biomarkers for Alzheimer\u2019s disease in clinical practice and trials. Nat Aging 3(5):506\u2013519. https:\/\/doi.org\/10.1038\/s43587-023-00403-3","journal-title":"Nat Aging"},{"key":"5219_CR62","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.dadm.2017.07.004","volume":"8","author":"N Fandos","year":"2017","unstructured":"Fandos N, P\u00e9rez-Grijalba V, Pesini P et al (2017) Plasma amyloid \u03b2 42\/40 ratios as biomarkers for amyloid \u03b2 cerebral deposition in cognitively normal individuals. Alzheimers Dement (Amst) 8:179\u2013187. https:\/\/doi.org\/10.1016\/j.dadm.2017.07.004","journal-title":"Alzheimers Dement (Amst)"},{"issue":"5","key":"5219_CR63","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1007\/s00401-021-02275-6","volume":"141","author":"NJ Ashton","year":"2021","unstructured":"Ashton NJ, Pascoal TA, Karikari TK et al (2021) Plasma p-tau231: a new biomarker for incipient Alzheimer\u2019s disease pathology. Acta Neuropathol 141(5):709\u2013724. https:\/\/doi.org\/10.1007\/s00401-021-02275-6","journal-title":"Acta Neuropathol"},{"issue":"3","key":"5219_CR64","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/s41591-020-0755-1","volume":"26","author":"S Janelidze","year":"2020","unstructured":"Janelidze S, Mattsson N, Palmqvist S et al (2020) Plasma p-tau181 in Alzheimer\u2019s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer\u2019s dementia. Nat Med 26(3):379\u2013386. https:\/\/doi.org\/10.1038\/s41591-020-0755-1","journal-title":"Nat Med"},{"issue":"1","key":"5219_CR65","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s13195-021-00805-8","volume":"13","author":"C Clark","year":"2021","unstructured":"Clark C, Lewczuk P, Kornhuber J et al (2021) Plasma neurofilament light and phosphorylated tau 181 as biomarkers of Alzheimer\u2019s disease pathology and clinical disease progression. Alzheimers Res Ther 13(1):65. https:\/\/doi.org\/10.1186\/s13195-021-00805-8","journal-title":"Alzheimers Res Ther"},{"issue":"9","key":"5219_CR66","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1021\/cn500101j","volume":"5","author":"KY Tzen","year":"2014","unstructured":"Tzen KY, Yang SY, Chen TF et al (2014) Plasma A\u03b2 but not tau is related to brain PiB retention in early Alzheimer\u2019s disease. ACS Chem Neurosci 5(9):830\u2013836. https:\/\/doi.org\/10.1021\/cn500101j","journal-title":"ACS Chem Neurosci"},{"issue":"4","key":"5219_CR67","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.3233\/jad-143018","volume":"48","author":"HJ Kim","year":"2015","unstructured":"Kim HJ, Park KW, Kim TE et al (2015) Elevation of the plasma A\u03b240\/A\u03b242 ratio as a diagnostic marker of sporadic early-onset Alzheimer\u2019s disease. J Alzheimers Dis 48(4):1043\u20131050. https:\/\/doi.org\/10.3233\/jad-143018","journal-title":"J Alzheimers Dis"},{"issue":"8","key":"5219_CR68","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/j.jalz.2017.06.2266","volume":"13","author":"V Ovod","year":"2017","unstructured":"Ovod V, Ramsey KN, Mawuenyega KG et al (2017) Amyloid \u03b2 concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis. Alzheimers Dement 13(8):841\u2013849. https:\/\/doi.org\/10.1016\/j.jalz.2017.06.2266","journal-title":"Alzheimers Dement"},{"issue":"4","key":"5219_CR69","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.3233\/jad-2010-090249","volume":"20","author":"JK Lui","year":"2010","unstructured":"Lui JK, Laws SM, Li QX et al (2010) Plasma amyloid-beta as a biomarker in Alzheimer\u2019s disease: the AIBL study of aging. J Alzheimers Dis 20(4):1233\u20131242. https:\/\/doi.org\/10.3233\/jad-2010-090249","journal-title":"J Alzheimers Dis"},{"key":"5219_CR70","doi-asserted-by":"publisher","DOI":"10.1038\/srep26801","volume":"6","author":"S Janelidze","year":"2016","unstructured":"Janelidze S, Stomrud E, Palmqvist S et al (2016) Plasma \u03b2-amyloid in Alzheimer\u2019s disease and vascular disease. Sci Rep 6:26801. https:\/\/doi.org\/10.1038\/srep26801","journal-title":"Sci Rep"},{"issue":"1","key":"5219_CR71","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3233\/jad-220765","volume":"92","author":"S Sedaghat","year":"2023","unstructured":"Sedaghat S, Ji Y, Hughes TM et al (2023) The association of kidney function with plasma amyloid-\u03b2 levels and brain amyloid deposition. J Alzheimers Dis 92(1):229\u2013239. https:\/\/doi.org\/10.3233\/jad-220765","journal-title":"J Alzheimers Dis"},{"issue":"4","key":"5219_CR72","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24043506","volume":"24","author":"JH Yoon","year":"2023","unstructured":"Yoon JH, Hwang J, Son SU et al (2023) How can insulin resistance cause Alzheimer\u2019s disease? Int J Mol Sci 24(4):3506. https:\/\/doi.org\/10.3390\/ijms24043506","journal-title":"Int J Mol Sci"},{"issue":"3","key":"5219_CR73","doi-asserted-by":"publisher","first-page":"695","DOI":"10.4103\/1673-5374.391305","volume":"20","author":"B Wu","year":"2025","unstructured":"Wu B, Liu Y, Li H et al (2025) Liver as a new target organ in Alzheimer\u2019s disease: insight from cholesterol metabolism and its role in amyloid-beta clearance. Neural Regen Res 20(3):695\u2013714. https:\/\/doi.org\/10.4103\/1673-5374.391305","journal-title":"Neural Regen Res"},{"issue":"2","key":"5219_CR74","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1038\/s41380-020-00923-z","volume":"26","author":"TK Karikari","year":"2021","unstructured":"Karikari TK, Benedet AL, Ashton NJ et al (2021) Diagnostic performance and prediction of clinical progression of plasma phospho-tau181 in the Alzheimer\u2019s disease neuroimaging initiative. Mol Psychiatry 26(2):429\u2013442. https:\/\/doi.org\/10.1038\/s41380-020-00923-z","journal-title":"Mol Psychiatry"},{"issue":"1","key":"5219_CR75","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1038\/s41467-020-15436-0","volume":"11","author":"S Janelidze","year":"2020","unstructured":"Janelidze S, Stomrud E, Smith R et al (2020) Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer\u2019s disease. Nat Commun 11(1):1683. https:\/\/doi.org\/10.1038\/s41467-020-15436-0","journal-title":"Nat Commun"},{"issue":"1","key":"5219_CR76","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s13195-020-00596-4","volume":"12","author":"NR Barth\u00e9lemy","year":"2020","unstructured":"Barth\u00e9lemy NR, Bateman RJ, Hirtz C et al (2020) Cerebrospinal fluid phospho-tau T217 outperforms T181 as a biomarker for the differential diagnosis of Alzheimer\u2019s disease and PET amyloid-positive patient identification. Alzheimers Res Ther 12(1):26. https:\/\/doi.org\/10.1186\/s13195-020-00596-4","journal-title":"Alzheimers Res Ther"},{"issue":"9","key":"5219_CR77","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/s1474-4422(21)00214-3","volume":"20","author":"EH Thijssen","year":"2021","unstructured":"Thijssen EH, La Joie R, Strom A et al (2021) Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer\u2019s disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study. Lancet Neurol 20(9):739\u2013752. https:\/\/doi.org\/10.1016\/s1474-4422(21)00214-3","journal-title":"Lancet Neurol"},{"issue":"9","key":"5219_CR78","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1038\/s41591-022-01925-w","volume":"28","author":"M Mil\u00e0-Alom\u00e0","year":"2022","unstructured":"Mil\u00e0-Alom\u00e0 M, Ashton NJ, Shekari M et al (2022) Plasma p-tau231 and p-tau217 as state markers of amyloid-\u03b2 pathology in preclinical Alzheimer\u2019s disease. Nat Med 28(9):1797\u20131801. https:\/\/doi.org\/10.1038\/s41591-022-01925-w","journal-title":"Nat Med"},{"issue":"8","key":"5219_CR79","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1001\/jama.2020.12134","volume":"324","author":"S Palmqvist","year":"2020","unstructured":"Palmqvist S, Janelidze S, Quiroz YT et al (2020) Discriminative accuracy of plasma phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders. JAMA 324(8):772\u2013781. https:\/\/doi.org\/10.1001\/jama.2020.12134","journal-title":"JAMA"},{"issue":"11","key":"5219_CR80","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20200861","volume":"217","author":"NR Barth\u00e9lemy","year":"2020","unstructured":"Barth\u00e9lemy NR, Horie K, Sato C, Bateman RJ (2020) Blood plasma phosphorylated-tau isoforms track CNS change in Alzheimer\u2019s disease. J Exp Med 217(11):e20200861. https:\/\/doi.org\/10.1084\/jem.20200861","journal-title":"J Exp Med"},{"issue":"3","key":"5219_CR81","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1002\/alz.12745","volume":"19","author":"L Beyer","year":"2022","unstructured":"Beyer L, Stocker H, Rujescu D et al (2022) Amyloid-beta misfolding and GFAP predict risk of clinical Alzheimer\u2019s disease diagnosis within 17 years. Alzheimer\u2019s Dement 19(3):1020\u20131028. https:\/\/doi.org\/10.1002\/alz.12745","journal-title":"Alzheimer's Dement"},{"issue":"18","key":"5219_CR82","doi-asserted-by":"publisher","first-page":"3865","DOI":"10.1002\/cne.24040","volume":"524","author":"CS von Bartheld","year":"2016","unstructured":"von Bartheld CS, Bahney J, Herculano-Houzel S (2016) The search for true numbers of neurons and glial cells in the human brain: a review of 150 years of cell counting. J Comp Neurol 524(18):3865\u20133895. https:\/\/doi.org\/10.1002\/cne.24040","journal-title":"J Comp Neurol"},{"issue":"11","key":"5219_CR83","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1016\/j.neurobiolaging.2007.04.013","volume":"29","author":"DP Pelvig","year":"2008","unstructured":"Pelvig DP, Pakkenberg H, Stark AK, Pakkenberg B (2008) Neocortical glial cell numbers in human brains. Neurobiol Aging 29(11):1754\u20131762. https:\/\/doi.org\/10.1016\/j.neurobiolaging.2007.04.013","journal-title":"Neurobiol Aging"},{"issue":"1\u20132","key":"5219_CR84","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.mce.2011.08.039","volume":"353","author":"A Verkhratsky","year":"2012","unstructured":"Verkhratsky A, Rodr\u00edguez JJ, Parpura V (2012) Calcium signalling in astroglia. Mol Cell Endocrinol 353(1\u20132):45\u201356. https:\/\/doi.org\/10.1016\/j.mce.2011.08.039","journal-title":"Mol Cell Endocrinol"},{"issue":"2","key":"5219_CR85","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.conb.2011.02.001","volume":"21","author":"ML Mayer","year":"2011","unstructured":"Mayer ML (2011) Structure and mechanism of glutamate receptor ion channel assembly, activation and modulation. Curr Opin Neurobiol 21(2):283\u2013290. https:\/\/doi.org\/10.1016\/j.conb.2011.02.001","journal-title":"Curr Opin Neurobiol"},{"issue":"4","key":"5219_CR86","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.nurt.2010.05.017","volume":"7","author":"A Verkhratsky","year":"2010","unstructured":"Verkhratsky A, Olabarria M, Noristani HN, Yeh CY, Rodriguez JJ (2010) Astrocytes in Alzheimer\u2019s disease. Neurotherapeutics 7(4):399\u2013412. https:\/\/doi.org\/10.1016\/j.nurt.2010.05.017","journal-title":"Neurotherapeutics"},{"issue":"3","key":"5219_CR87","doi-asserted-by":"publisher","first-page":"699","DOI":"10.3233\/jad-2010-101089","volume":"22","author":"AJ Vincent","year":"2010","unstructured":"Vincent AJ, Gasperini R, Foa L, Small DH (2010) Astrocytes in Alzheimer\u2019s disease: emerging roles in calcium dysregulation and synaptic plasticity. J Alzheimers Dis 22(3):699\u2013714. https:\/\/doi.org\/10.3233\/jad-2010-101089","journal-title":"J Alzheimers Dis"},{"issue":"2","key":"5219_CR88","doi-asserted-by":"publisher","first-page":"a020420","DOI":"10.1101\/cshperspect.a020420","volume":"7","author":"MV Sofroniew","year":"2014","unstructured":"Sofroniew MV (2014) Astrogliosis. Cold Spring Harb Perspect Biol 7(2):a020420. https:\/\/doi.org\/10.1101\/cshperspect.a020420","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"3","key":"5219_CR89","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1002\/glia.23270","volume":"66","author":"A Gomez-Arboledas","year":"2018","unstructured":"Gomez-Arboledas A, Davila JC, Sanchez-Mejias E et al (2018) Phagocytic clearance of presynaptic dystrophies by reactive astrocytes in Alzheimer\u2019s disease. Glia 66(3):637\u2013653. https:\/\/doi.org\/10.1002\/glia.23270","journal-title":"Glia"},{"issue":"15","key":"5219_CR90","doi-asserted-by":"publisher","first-page":"4023","DOI":"10.1523\/jneurosci.3442-16.2017","volume":"37","author":"CC Liu","year":"2017","unstructured":"Liu CC, Hu J, Zhao N et al (2017) Astrocytic LRP1 mediates brain A\u03b2 clearance and impacts amyloid deposition. J Neurosci 37(15):4023\u20134031. https:\/\/doi.org\/10.1523\/jneurosci.3442-16.2017","journal-title":"J Neurosci"},{"issue":"10","key":"5219_CR91","first-page":"4082","volume":"8","author":"RX Liu","year":"2016","unstructured":"Liu RX, Huang C, Bennett DA, Li H, Wang R (2016) The characteristics of astrocyte on A\u03b2 clearance altered in Alzheimer\u2019s disease were reversed by anti-inflammatory agent (+)-2-(1-hydroxyl-4-oxocyclohexyl) ethyl caffeate. Am J Transl Res 8(10):4082\u20134094","journal-title":"Am J Transl Res"},{"issue":"4","key":"5219_CR92","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1002\/glia.22619","volume":"62","author":"SD Mulder","year":"2014","unstructured":"Mulder SD, Nielsen HM, Blankenstein MA, Eikelenboom P, Veerhuis R (2014) Apolipoproteins E and J interfere with amyloid-beta uptake by primary human astrocytes and microglia in vitro. Glia 62(4):493\u2013503. https:\/\/doi.org\/10.1002\/glia.22619","journal-title":"Glia"},{"issue":"1","key":"5219_CR93","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.expneurol.2011.11.001","volume":"233","author":"SD Mulder","year":"2012","unstructured":"Mulder SD, Veerhuis R, Blankenstein MA, Nielsen HM (2012) The effect of amyloid associated proteins on the expression of genes involved in amyloid-\u03b2 clearance by adult human astrocytes. Exp Neurol 233(1):373\u2013379. https:\/\/doi.org\/10.1016\/j.expneurol.2011.11.001","journal-title":"Exp Neurol"},{"issue":"4","key":"5219_CR94","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1002\/jnr.490230405","volume":"23","author":"K Mokuno","year":"1989","unstructured":"Mokuno K, Kamholz J, Behrman T et al (1989) Neuronal modulation of Schwann cell glial fibrillary acidic protein (GFAP). J Neurosci Res 23(4):396\u2013405. https:\/\/doi.org\/10.1002\/jnr.490230405","journal-title":"J Neurosci Res"},{"issue":"11","key":"5219_CR95","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1038\/nrgastro.2012.138","volume":"9","author":"BD Gulbransen","year":"2012","unstructured":"Gulbransen BD, Sharkey KA (2012) Novel functional roles for enteric glia in the gastrointestinal tract. Nat Rev Gastroenterol Hepatol 9(11):625\u2013632. https:\/\/doi.org\/10.1038\/nrgastro.2012.138","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"8","key":"5219_CR96","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1002\/ar.24128","volume":"302","author":"D Grundmann","year":"2019","unstructured":"Grundmann D, Loris E, Maas-Omlor S et al (2019) Enteric Glia: S100, GFAP, and beyond. Anat Rec (Hoboken) 302(8):1333\u20131344. https:\/\/doi.org\/10.1002\/ar.24128","journal-title":"Anat Rec (Hoboken)"},{"issue":"6","key":"5219_CR97","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1002\/glia.22800","volume":"63","author":"W Kamphuis","year":"2015","unstructured":"Kamphuis W, Kooijman L, Orre M et al (2015) GFAP and vimentin deficiency alters gene expression in astrocytes and microglia in wild-type mice and changes the transcriptional response of reactive glia in mouse model for Alzheimer\u2019s disease. Glia 63(6):1036\u20131056. https:\/\/doi.org\/10.1002\/glia.22800","journal-title":"Glia"},{"issue":"12","key":"5219_CR98","doi-asserted-by":"publisher","first-page":"2746","DOI":"10.1016\/j.neurobiolaging.2014.06.004","volume":"35","author":"M Orre","year":"2014","unstructured":"Orre M, Kamphuis W, Osborn LM et al (2014) Isolation of glia from Alzheimer\u2019s mice reveals inflammation and dysfunction. Neurobiol Aging 35(12):2746\u20132760. https:\/\/doi.org\/10.1016\/j.neurobiolaging.2014.06.004","journal-title":"Neurobiol Aging"},{"issue":"4","key":"5219_CR99","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1152\/physrev.00041.2013","volume":"94","author":"M Pekny","year":"2014","unstructured":"Pekny M, Pekna M (2014) Astrocyte reactivity and reactive astrogliosis: costs and benefits. Physiol Rev 94(4):1077\u20131098. https:\/\/doi.org\/10.1152\/physrev.00041.2013","journal-title":"Physiol Rev"},{"issue":"6","key":"5219_CR100","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.annemergmed.2011.08.021","volume":"59","author":"L Papa","year":"2012","unstructured":"Papa L, Lewis LM, Falk JL et al (2012) Elevated levels of serum glial fibrillary acidic protein breakdown products in mild and moderate traumatic brain injury are associated with intracranial lesions and neurosurgical intervention. Ann Emerg Med 59(6):471\u2013483. https:\/\/doi.org\/10.1016\/j.annemergmed.2011.08.021","journal-title":"Ann Emerg Med"},{"key":"5219_CR101","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2020.102785","volume":"56","author":"E Czeiter","year":"2020","unstructured":"Czeiter E, Amrein K, Gravesteijn BY et al (2020) Blood biomarkers on admission in acute traumatic brain injury: relations to severity, CT findings and care path in the CENTER-TBI study. EBioMedicine 56:102785. https:\/\/doi.org\/10.1016\/j.ebiom.2020.102785","journal-title":"EBioMedicine"},{"issue":"4","key":"5219_CR102","doi-asserted-by":"publisher","DOI":"10.3390\/biom13040692","volume":"13","author":"Z Qian","year":"2023","unstructured":"Qian Z, Qin J, Lai Y, Zhang C, Zhang X (2023) Large-scale integration of single-cell RNA-seq data reveals astrocyte diversity and transcriptomic modules across six central nervous system disorders. Biomolecules 13(4):692. https:\/\/doi.org\/10.3390\/biom13040692","journal-title":"Biomolecules"},{"issue":"11","key":"5219_CR103","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1016\/j.neuron.2022.03.008","volume":"110","author":"JS Sadick","year":"2022","unstructured":"Sadick JS, O\u2019Dea MR, Hasel P et al (2022) Astrocytes and oligodendrocytes undergo subtype-specific transcriptional changes in Alzheimer\u2019s disease. Neuron 110(11):1788-1805.e1710. https:\/\/doi.org\/10.1016\/j.neuron.2022.03.008","journal-title":"Neuron"},{"issue":"12","key":"5219_CR104","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1038\/s41593-019-0539-4","volume":"22","author":"A Grubman","year":"2019","unstructured":"Grubman A, Chew G, Ouyang JF et al (2019) A single-cell atlas of entorhinal cortex from individuals with Alzheimer\u2019s disease reveals cell-type-specific gene expression regulation. Nat Neurosci 22(12):2087\u20132097. https:\/\/doi.org\/10.1038\/s41593-019-0539-4","journal-title":"Nat Neurosci"},{"issue":"7761","key":"5219_CR105","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1038\/s41586-019-1195-2","volume":"570","author":"H Mathys","year":"2019","unstructured":"Mathys H, Davila-Velderrain J, Peng Z et al (2019) Single-cell transcriptomic analysis of Alzheimer\u2019s disease. Nature 570(7761):332\u2013337. https:\/\/doi.org\/10.1038\/s41586-019-1195-2","journal-title":"Nature"},{"issue":"6","key":"5219_CR106","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1038\/s41593-020-0624-8","volume":"23","author":"N Habib","year":"2020","unstructured":"Habib N, McCabe C, Medina S et al (2020) Disease-associated astrocytes in Alzheimer\u2019s disease and aging. Nat Neurosci 23(6):701\u2013706. https:\/\/doi.org\/10.1038\/s41593-020-0624-8","journal-title":"Nat Neurosci"},{"issue":"1","key":"5219_CR107","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/s12276-023-01148-0","volume":"56","author":"J Kim","year":"2024","unstructured":"Kim J, Yoo ID, Lim J, Moon JS (2024) Pathological phenotypes of astrocytes in Alzheimer\u2019s disease. Exp Mol Med 56(1):95\u201399. https:\/\/doi.org\/10.1038\/s12276-023-01148-0","journal-title":"Exp Mol Med"},{"key":"5219_CR108","doi-asserted-by":"publisher","unstructured":"Wei H, Withrow J, Rakshit J et al (2024) The identification of a distinct astrocyte subtype that diminishes in Alzheimer\u2019s disease. Aging Dis 15(6):2752\u20132769. https:\/\/doi.org\/10.14336\/ad.2024.0205-1","DOI":"10.14336\/ad.2024.0205-1"},{"issue":"9","key":"5219_CR109","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1007\/s11547-023-01675-w","volume":"128","author":"Y-C Wei","year":"2023","unstructured":"Wei Y-C, Hsu C-CH, Huang W-Y et al (2023) Vascular risk factors and astrocytic marker for the glymphatic system activity. Radiol Med 128(9):1148\u20131161. https:\/\/doi.org\/10.1007\/s11547-023-01675-w","journal-title":"Radiol Med"},{"issue":"2","key":"5219_CR110","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41591-018-0297-y","volume":"25","author":"DA Nation","year":"2019","unstructured":"Nation DA, Sweeney MD, Montagne A et al (2019) Blood\u2013brain barrier breakdown is an early biomarker of human cognitive dysfunction. Nat Med 25(2):270\u2013276. https:\/\/doi.org\/10.1038\/s41591-018-0297-y","journal-title":"Nat Med"},{"key":"5219_CR111","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2019.00280","volume":"10","author":"A Abdelhak","year":"2019","unstructured":"Abdelhak A, Hottenrott T, Morenas-Rodr\u00edguez E et al (2019) Glial activation markers in CSF and serum from patients with primary progressive multiple sclerosis: potential of serum GFAP as disease severity marker? Front Neurol 10:280. https:\/\/doi.org\/10.3389\/fneur.2019.00280","journal-title":"Front Neurol"},{"issue":"1","key":"5219_CR112","doi-asserted-by":"publisher","first-page":"10923","DOI":"10.1038\/s41598-020-67934-2","volume":"10","author":"X Ayrignac","year":"2020","unstructured":"Ayrignac X, Le Bars E, Duflos C et al (2020) Serum GFAP in multiple sclerosis: correlation with disease type and MRI markers of disease severity. Sci Rep 10(1):10923. https:\/\/doi.org\/10.1038\/s41598-020-67934-2","journal-title":"Sci Rep"},{"issue":"2","key":"5219_CR113","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1111\/jnc.13399","volume":"136","author":"A Ishiki","year":"2016","unstructured":"Ishiki A, Kamada M, Kawamura Y et al (2016) Glial fibrillar acidic protein in the cerebrospinal fluid of Alzheimer\u2019s disease, dementia with Lewy bodies, and frontotemporal lobar degeneration. J Neurochem 136(2):258\u2013261. https:\/\/doi.org\/10.1111\/jnc.13399","journal-title":"J Neurochem"},{"issue":"3","key":"5219_CR114","doi-asserted-by":"publisher","first-page":"541","DOI":"10.3233\/jad-2009-1075","volume":"17","author":"S Jesse","year":"2009","unstructured":"Jesse S, Steinacker P, Cepek L et al (2009) Glial fibrillary acidic protein and protein S-100B: different concentration pattern of glial proteins in cerebrospinal fluid of patients with Alzheimer\u2019s disease and Creutzfeldt-Jakob disease. J Alzheimers Dis 17(3):541\u2013551. https:\/\/doi.org\/10.3233\/jad-2009-1075","journal-title":"J Alzheimers Dis"},{"issue":"8","key":"5219_CR115","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1089\/neu.2014.3635","volume":"32","author":"PJ McMahon","year":"2015","unstructured":"McMahon PJ, Panczykowski DM, Yue JK et al (2015) Measurement of the glial fibrillary acidic protein and its breakdown products GFAP-BDP biomarker for the detection of traumatic brain injury compared to computed tomography and magnetic resonance imaging. J Neurotrauma 32(8):527\u2013533. https:\/\/doi.org\/10.1089\/neu.2014.3635","journal-title":"J Neurotrauma"},{"issue":"3","key":"5219_CR116","doi-asserted-by":"publisher","first-page":"e221302","DOI":"10.1001\/jamanetworkopen.2022.1302","volume":"5","author":"L Papa","year":"2022","unstructured":"Papa L, Ladde JG, O\u2019Brien JF et al (2022) Evaluation of glial and neuronal blood biomarkers compared with clinical decision rules in assessing the need for computed tomography in patients with mild traumatic brain injury. JAMA Netw Open 5(3):e221302\u2013e221302. https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.1302","journal-title":"JAMA Netw Open"},{"key":"5219_CR117","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.ceb.2015.02.004","volume":"32","author":"EM Hol","year":"2015","unstructured":"Hol EM, Pekny M (2015) Glial fibrillary acidic protein (GFAP) and the astrocyte intermediate filament system in diseases of the central nervous system. Curr Opin Cell Biol 32:121\u2013130. https:\/\/doi.org\/10.1016\/j.ceb.2015.02.004","journal-title":"Curr Opin Cell Biol"},{"issue":"5","key":"5219_CR118","doi-asserted-by":"publisher","first-page":"e258842","DOI":"10.1001\/jamanetworkopen.2025.8842","volume":"8","author":"SH Kang","year":"2025","unstructured":"Kang SH, Lee EH, Kim YJ et al (2025) Cerebral amyloid angiopathy and downstream Alzheimer disease plasma biomarkers. JAMA Netw Open 8(5):e258842\u2013e258842. https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.8842","journal-title":"JAMA Netw Open"},{"issue":"6","key":"5219_CR119","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1093\/brain\/awad101","volume":"146","author":"TH Mok","year":"2023","unstructured":"Mok TH, Nihat A, Majbour N et al (2023) Seed amplification and neurodegeneration marker trajectories in individuals at risk of prion disease. Brain 146(6):2570\u20132583. https:\/\/doi.org\/10.1093\/brain\/awad101","journal-title":"Brain"},{"key":"5219_CR120","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2023.1107369","volume":"10","author":"X Liu","year":"2023","unstructured":"Liu X, Wang Y, Wu J et al (2023) Emergence delirium and postoperative delirium associated with high plasma NfL and GFAP: an observational study. Front Med (Lausanne) 10:1107369. https:\/\/doi.org\/10.3389\/fmed.2023.1107369","journal-title":"Front Med (Lausanne)"},{"key":"5219_CR121","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2024.1356575","volume":"15","author":"JHA Piel","year":"2024","unstructured":"Piel JHA, Bargemann L, Leypoldt F, Wandinger KP, Dargvainiene J (2024) Serum NFL and tau, but not serum UCHL-1 and GFAP or CSF SNAP-25, NPTX2, or sTREM2, correlate with delirium in a 3-year retrospective analysis. Front Neurol 15:1356575. https:\/\/doi.org\/10.3389\/fneur.2024.1356575","journal-title":"Front Neurol"},{"issue":"2","key":"5219_CR122","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/j.bja.2020.08.061","volume":"126","author":"T Ballweg","year":"2021","unstructured":"Ballweg T, White M, Parker M et al (2021) Association between plasma tau and postoperative delirium incidence and severity: a prospective observational study. Br J Anaesth 126(2):458\u2013466. https:\/\/doi.org\/10.1016\/j.bja.2020.08.061","journal-title":"Br J Anaesth"},{"issue":"4","key":"5219_CR123","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1097\/aln.0000000000004666","volume":"139","author":"JM Leung","year":"2023","unstructured":"Leung JM, Rojas JC, Tang C et al (2023) Presence of preoperative neurodegeneration biofluid markers in patients with postoperative delirium. Anesthesiology 139(4):432\u2013443. https:\/\/doi.org\/10.1097\/aln.0000000000004666","journal-title":"Anesthesiology"},{"key":"5219_CR124","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1186\/s13054-015-1081-8","volume":"19","author":"J Lei","year":"2015","unstructured":"Lei J, Gao G, Feng J et al (2015) Glial fibrillary acidic protein as a biomarker in severe traumatic brain injury patients: a prospective cohort study. Crit Care 19:362. https:\/\/doi.org\/10.1186\/s13054-015-1081-8","journal-title":"Crit Care"},{"issue":"1","key":"5219_CR125","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s12987-020-00230-3","volume":"17","author":"H Kadry","year":"2020","unstructured":"Kadry H, Noorani B, Cucullo L (2020) A blood\u2013brain barrier overview on structure, function, impairment, and biomarkers of integrity. Fluids Barriers CNS 17(1):69. https:\/\/doi.org\/10.1186\/s12987-020-00230-3","journal-title":"Fluids Barriers CNS"},{"issue":"1","key":"5219_CR126","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.nbd.2009.07.030","volume":"37","author":"NJ Abbott","year":"2010","unstructured":"Abbott NJ, Patabendige AA, Dolman DE, Yusof SR, Begley DJ (2010) Structure and function of the blood-brain barrier. Neurobiol Dis 37(1):13\u201325. https:\/\/doi.org\/10.1016\/j.nbd.2009.07.030","journal-title":"Neurobiol Dis"},{"issue":"12","key":"5219_CR127","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1172\/jci10498","volume":"106","author":"M Shibata","year":"2000","unstructured":"Shibata M, Yamada S, Kumar SR et al (2000) Clearance of Alzheimer\u2019s amyloid-ss(1\u201340) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. J Clin Invest 106(12):1489\u20131499. https:\/\/doi.org\/10.1172\/jci10498","journal-title":"J Clin Invest"},{"issue":"3","key":"5219_CR128","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.neulet.2006.03.047","volume":"401","author":"S Marco","year":"2006","unstructured":"Marco S, Skaper SD (2006) Amyloid beta-peptide1-42 alters tight junction protein distribution and expression in brain microvessel endothelial cells. Neurosci Lett 401(3):219\u2013224. https:\/\/doi.org\/10.1016\/j.neulet.2006.03.047","journal-title":"Neurosci Lett"},{"issue":"10","key":"5219_CR129","doi-asserted-by":"publisher","first-page":"5795","DOI":"10.1073\/pnas.95.10.5795","volume":"95","author":"KT Akama","year":"1998","unstructured":"Akama KT, Albanese C, Pestell RG, Van Eldik LJ (1998) Amyloid beta-peptide stimulates nitric oxide production in astrocytes through an NFkappaB-dependent mechanism. Proc Natl Acad Sci U S A 95(10):5795\u20135800. https:\/\/doi.org\/10.1073\/pnas.95.10.5795","journal-title":"Proc Natl Acad Sci U S A"},{"key":"5219_CR130","doi-asserted-by":"publisher","DOI":"10.1186\/2045-8118-11-10","volume":"11","author":"T Brinker","year":"2014","unstructured":"Brinker T, Stopa E, Morrison J, Klinge P (2014) A new look at cerebrospinal fluid circulation. Fluids Barriers CNS 11:10. https:\/\/doi.org\/10.1186\/2045-8118-11-10","journal-title":"Fluids Barriers CNS"},{"key":"5219_CR131","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/b978-0-12-804279-3.00002-2","volume":"146","author":"H Tumani","year":"2017","unstructured":"Tumani H, Huss A, Bachhuber F (2017) The cerebrospinal fluid and barriers - anatomic and physiologic considerations. Handb Clin Neurol 146:21\u201332. https:\/\/doi.org\/10.1016\/b978-0-12-804279-3.00002-2","journal-title":"Handb Clin Neurol"},{"issue":"6","key":"5219_CR132","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.tins.2015.04.003","volume":"38","author":"Z Yang","year":"2015","unstructured":"Yang Z, Wang KK (2015) Glial fibrillary acidic protein: from intermediate filament assembly and gliosis to neurobiomarker. Trends Neurosci 38(6):364\u2013374. https:\/\/doi.org\/10.1016\/j.tins.2015.04.003","journal-title":"Trends Neurosci"},{"key":"5219_CR133","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02802","volume":"9","author":"F Shan","year":"2018","unstructured":"Shan F, Long Y, Qiu W (2018) Autoimmune glial fibrillary acidic protein astrocytopathy: a review of the literature. Front Immunol 9:2802. https:\/\/doi.org\/10.3389\/fimmu.2018.02802","journal-title":"Front Immunol"},{"issue":"3","key":"5219_CR134","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1038\/s41582-021-00616-3","volume":"18","author":"A Abdelhak","year":"2022","unstructured":"Abdelhak A, Foschi M, Abu-Rumeileh S et al (2022) Blood GFAP as an emerging biomarker in brain and spinal cord disorders. Nat Rev Neurol 18(3):158\u2013172. https:\/\/doi.org\/10.1038\/s41582-021-00616-3","journal-title":"Nat Rev Neurol"},{"key":"5219_CR135","doi-asserted-by":"publisher","first-page":"e47789","DOI":"10.7554\/eLife.47789","volume":"8","author":"RA Battaglia","year":"2019","unstructured":"Battaglia RA, Beltran AS, Delic S et al (2019) Site-specific phosphorylation and caspase cleavage of GFAP are new markers of Alexander disease severity. Elife 8:e47789. https:\/\/doi.org\/10.7554\/eLife.47789","journal-title":"Elife"},{"issue":"1","key":"5219_CR136","doi-asserted-by":"publisher","first-page":"37","DOI":"10.2967\/jnumed.110.087031","volume":"53","author":"SF Carter","year":"2012","unstructured":"Carter SF, Sch\u00f6ll M, Almkvist O et al (2012) Evidence for astrocytosis in prodromal Alzheimer disease provided by 11C-deuterium-L-deprenyl: a multitracer PET paradigm combining 11C-Pittsburgh compound B and 18F-FDG. J Nucl Med 53(1):37\u201346. https:\/\/doi.org\/10.2967\/jnumed.110.087031","journal-title":"J Nucl Med"},{"key":"5219_CR137","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2016.00160","volume":"8","author":"M Ries","year":"2016","unstructured":"Ries M, Sastre M (2016) Mechanisms of A\u03b2 clearance and degradation by glial cells. Front Aging Neurosci 8:160. https:\/\/doi.org\/10.3389\/fnagi.2016.00160","journal-title":"Front Aging Neurosci"},{"issue":"8","key":"5219_CR138","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1097\/NEN.0b013e3181afe475","volume":"68","author":"JS Miners","year":"2009","unstructured":"Miners JS, Baig S, Tayler H, Kehoe PG, Love S (2009) Neprilysin and insulin-degrading enzyme levels are increased in Alzheimer disease in relation to disease severity. J Neuropathol Exp Neurol 68(8):902\u2013914. https:\/\/doi.org\/10.1097\/NEN.0b013e3181afe475","journal-title":"J Neuropathol Exp Neurol"},{"key":"5219_CR139","doi-asserted-by":"publisher","first-page":"4567","DOI":"10.1007\/s00259-022-05897-4","volume":"49","author":"G Salvad\u00f3","year":"2022","unstructured":"Salvad\u00f3 G, Mil\u00e0-Alom\u00e0 M, Shekari M et al (2022) Reactive astrogliosis is associated with higher cerebral glucose consumption in the early Alzheimer\u2019s continuum. Eur J Nucl Med Mol Imaging 49:4567\u20134579. https:\/\/doi.org\/10.1007\/s00259-022-05897-4","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"15","key":"5219_CR140","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22157887","volume":"22","author":"C Nanclares","year":"2021","unstructured":"Nanclares C, Baraibar AM, Araque A, Kofuji P (2021) Dysregulation of astrocyte-neuronal communication in Alzheimer\u2019s disease. Int J Mol Sci 22(15):7887. https:\/\/doi.org\/10.3390\/ijms22157887","journal-title":"Int J Mol Sci"},{"key":"5219_CR141","doi-asserted-by":"publisher","DOI":"10.3389\/fnmol.2017.00427","volume":"10","author":"RE Gonz\u00e1lez-Reyes","year":"2017","unstructured":"Gonz\u00e1lez-Reyes RE, Nava-Mesa MO, Vargas-S\u00e1nchez K, Ariza-Salamanca D, Mora-Mu\u00f1oz L (2017) Involvement of astrocytes in Alzheimer\u2019s disease from a neuroinflammatory and oxidative stress perspective. Front Mol Neurosci 10:427. https:\/\/doi.org\/10.3389\/fnmol.2017.00427","journal-title":"Front Mol Neurosci"},{"key":"5219_CR142","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.biochi.2020.02.003","volume":"171\u2013172","author":"S Elangovan","year":"2020","unstructured":"Elangovan S, Holsinger RMD (2020) Cyclical amyloid beta-astrocyte activity induces oxidative stress in Alzheimer\u2019s disease. Biochimie 171\u2013172:38\u201342. https:\/\/doi.org\/10.1016\/j.biochi.2020.02.003","journal-title":"Biochimie"},{"issue":"3","key":"5219_CR143","doi-asserted-by":"publisher","first-page":"555","DOI":"10.3233\/jad-2012-120469","volume":"31","author":"M Matos","year":"2012","unstructured":"Matos M, Augusto E, Machado NJ et al (2012) Astrocytic adenosine A2A receptors control the amyloid-\u03b2 peptide-induced decrease of glutamate uptake. J Alzheimers Dis 31(3):555\u2013567. https:\/\/doi.org\/10.3233\/jad-2012-120469","journal-title":"J Alzheimers Dis"},{"issue":"5","key":"5219_CR144","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1002\/ana.410350507","volume":"35","author":"IA Simpson","year":"1994","unstructured":"Simpson IA, Chundu KR, Davies-Hill T, Honer WG, Davies P (1994) Decreased concentrations of GLUT1 and GLUT3 glucose transporters in the brains of patients with Alzheimer\u2019s disease. Ann Neurol 35(5):546\u2013551. https:\/\/doi.org\/10.1002\/ana.410350507","journal-title":"Ann Neurol"},{"issue":"4","key":"5219_CR145","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/s1474-4422(15)70016-5","volume":"14","author":"MT Heneka","year":"2015","unstructured":"Heneka MT, Carson MJ, El Khoury J et al (2015) Neuroinflammation in Alzheimer\u2019s disease. Lancet Neurol 14(4):388\u2013405. https:\/\/doi.org\/10.1016\/s1474-4422(15)70016-5","journal-title":"Lancet Neurol"},{"issue":"2","key":"5219_CR146","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/0006-8993(71)90668-8","volume":"28","author":"LF Eng","year":"1971","unstructured":"Eng LF, Vanderhaeghen JJ, Bignami A, Gerstl B (1971) An acidic protein isolated from fibrous astrocytes. Brain Res 28(2):351\u2013354. https:\/\/doi.org\/10.1016\/0006-8993(71)90668-8","journal-title":"Brain Res"},{"issue":"5","key":"5219_CR147","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1006\/jmbi.1999.2528","volume":"286","author":"H Herrmann","year":"1999","unstructured":"Herrmann H, H\u00e4ner M, Brettel M, Ku NO, Aebi U (1999) Characterization of distinct early assembly units of different intermediate filament proteins. J Mol Biol 286(5):1403\u20131420. https:\/\/doi.org\/10.1006\/jmbi.1999.2528","journal-title":"J Mol Biol"},{"issue":"Pt 7","key":"5219_CR148","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1242\/jcs.107.7.1935","volume":"107","author":"JE Ralton","year":"1994","unstructured":"Ralton JE, Lu X, Hutcheson AM, Quinlan RA (1994) Identification of two N-terminal non-alpha-helical domain motifs important in the assembly of glial fibrillary acidic protein. J Cell Sci 107(Pt 7):1935\u20131948. https:\/\/doi.org\/10.1242\/jcs.107.7.1935","journal-title":"J Cell Sci"},{"issue":"5","key":"5219_CR149","first-page":"1553","volume":"51","author":"E Bongcam-Rudloff","year":"1991","unstructured":"Bongcam-Rudloff E, Nist\u00e9r M, Betsholtz C et al (1991) Human glial fibrillary acidic protein: complementary DNA cloning, chromosome localization, and messenger RNA expression in human glioma cell lines of various phenotypes. Cancer Res 51(5):1553\u20131560","journal-title":"Cancer Res"},{"issue":"3","key":"5219_CR150","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.neurobiolaging.2013.09.035","volume":"35","author":"W Kamphuis","year":"2014","unstructured":"Kamphuis W, Middeldorp J, Kooijman L et al (2014) Glial fibrillary acidic protein isoform expression in plaque related astrogliosis in Alzheimer\u2019s disease. Neurobiol Aging 35(3):492\u2013510. https:\/\/doi.org\/10.1016\/j.neurobiolaging.2013.09.035","journal-title":"Neurobiol Aging"},{"issue":"13","key":"5219_CR151","doi-asserted-by":"publisher","first-page":"5178","DOI":"10.1073\/pnas.86.13.5178","volume":"86","author":"SA Reeves","year":"1989","unstructured":"Reeves SA, Helman LJ, Allison A, Israel MA (1989) Molecular cloning and primary structure of human glial fibrillary acidic protein. Proc Natl Acad Sci U S A 86(13):5178\u20135182. https:\/\/doi.org\/10.1073\/pnas.86.13.5178","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"5219_CR152","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/jnr.490320102","volume":"32","author":"DL Feinstein","year":"1992","unstructured":"Feinstein DL, Weinmaster GA, Milner RJ (1992) Isolation of cDNA clones encoding rat glial fibrillary acidic protein: expression in astrocytes and in Schwann cells. J Neurosci Res 32(1):1\u201314. https:\/\/doi.org\/10.1002\/jnr.490320102","journal-title":"J Neurosci Res"},{"issue":"4","key":"5219_CR153","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1002\/jnr.490410404","volume":"41","author":"E Galea","year":"1995","unstructured":"Galea E, Dupouey P, Feinstein DL (1995) Glial fibrillary acidic protein mRNA isotypes: expression in vitro and in vivo. J Neurosci Res 41(4):452\u2013461. https:\/\/doi.org\/10.1002\/jnr.490410404","journal-title":"J Neurosci Res"},{"issue":"2","key":"5219_CR154","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/0169-328x(95)00010-p","volume":"30","author":"D Zelenika","year":"1995","unstructured":"Zelenika D, Grima B, Brenner M, Pessac B (1995) A novel glial fibrillary acidic protein mRNA lacking exon 1. Brain Res Mol Brain Res 30(2):251\u2013258. https:\/\/doi.org\/10.1016\/0169-328x(95)00010-p","journal-title":"Brain Res Mol Brain Res"},{"issue":"4","key":"5219_CR155","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1002\/glia.20243","volume":"52","author":"RF Roelofs","year":"2005","unstructured":"Roelofs RF, Fischer DF, Houtman SH et al (2005) Adult human subventricular, subgranular, and subpial zones contain astrocytes with a specialized intermediate filament cytoskeleton. Glia 52(4):289\u2013300. https:\/\/doi.org\/10.1002\/glia.20243","journal-title":"Glia"},{"issue":"2","key":"5219_CR156","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1242\/dev.041632","volume":"137","author":"J Middeldorp","year":"2010","unstructured":"Middeldorp J, Boer K, Sluijs JA et al (2010) GFAPdelta in radial glia and subventricular zone progenitors in the developing human cortex. Development 137(2):313\u2013321. https:\/\/doi.org\/10.1242\/dev.041632","journal-title":"Development"},{"issue":"3","key":"5219_CR157","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1002\/(SICI)1097-4547(19990501)56:3<219::AID-JNR1>3.0.CO;2-2","volume":"56","author":"DF Condorelli","year":"1999","unstructured":"Condorelli DF, Nicoletti VG, Barresi V et al (1999) Structural features of the rat GFAP gene and identification of a novel alternative transcript. J Neurosci Res 56(3):219\u2013228. https:\/\/doi.org\/10.1002\/(SICI)1097-4547(19990501)56:3%3c219::AID-JNR1%3e3.0.CO;2-2","journal-title":"J Neurosci Res"},{"issue":"5","key":"5219_CR158","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1002\/glia.20475","volume":"55","author":"J Blechingberg","year":"2007","unstructured":"Blechingberg J, Holm IE, Nielsen KB et al (2007) Identification and characterization of GFAPkappa, a novel glial fibrillary acidic protein isoform. Glia 55(5):497\u2013507. https:\/\/doi.org\/10.1002\/glia.20475","journal-title":"Glia"},{"issue":"8","key":"5219_CR159","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0042823","volume":"7","author":"W Kamphuis","year":"2012","unstructured":"Kamphuis W, Mamber C, Moeton M et al (2012) GFAP isoforms in adult mouse brain with a focus on neurogenic astrocytes and reactive astrogliosis in mouse models of Alzheimer disease. PLoS ONE 7(8):e42823. https:\/\/doi.org\/10.1371\/journal.pone.0042823","journal-title":"PLoS ONE"},{"key":"5219_CR160","doi-asserted-by":"publisher","DOI":"10.1016\/j.ceb.2024.102340","volume":"87","author":"AJEM de Reus","year":"2024","unstructured":"de Reus AJEM, Basak O, Dykstra W et al (2024) GFAP-isoforms in the nervous system: understanding the need for diversity. Curr Opin Cell Biol 87:102340. https:\/\/doi.org\/10.1016\/j.ceb.2024.102340","journal-title":"Curr Opin Cell Biol"},{"issue":"6","key":"5219_CR161","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1002\/humu.24008","volume":"41","author":"G Helman","year":"2020","unstructured":"Helman G, Takanohashi A, Hagemann TL et al (2020) Type II Alexander disease caused by splicing errors and aberrant overexpression of an uncharacterized GFAP isoform. Hum Mutat 41(6):1131\u20131137. https:\/\/doi.org\/10.1002\/humu.24008","journal-title":"Hum Mutat"},{"issue":"3","key":"5219_CR162","doi-asserted-by":"publisher","DOI":"10.1096\/fj.202001767R","volume":"35","author":"EJ van Bodegraven","year":"2021","unstructured":"van Bodegraven EJ, Sluijs JA, Tan AK, Robe PAJT, Hol EM (2021) New GFAP splice isoform (GFAP\u00b5) differentially expressed in glioma translates into 21 kDa N-terminal GFAP protein. FASEB J 35(3):e21389. https:\/\/doi.org\/10.1096\/fj.202001767R","journal-title":"FASEB J"},{"issue":"9","key":"5219_CR163","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1038\/sj.mp.4001379","volume":"8","author":"EM Hol","year":"2003","unstructured":"Hol EM, Roelofs RF, Moraal E et al (2003) Neuronal expression of GFAP in patients with Alzheimer pathology and identification of novel GFAP splice forms. Mol Psychiatry 8(9):786\u2013796. https:\/\/doi.org\/10.1038\/sj.mp.4001379","journal-title":"Mol Psychiatry"},{"issue":"11","key":"5219_CR164","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0007663","volume":"4","author":"J Middeldorp","year":"2009","unstructured":"Middeldorp J, van den Berge SA, Aronica E, Speijer D, Hol EM (2009) Specific human astrocyte subtype revealed by affinity purified GFAP+1 antibody; unpurified serum cross-reacts with neurofilament-L in Alzheimer. PLoS ONE 4(11):e7663. https:\/\/doi.org\/10.1371\/journal.pone.0007663","journal-title":"PLoS ONE"},{"issue":"1","key":"5219_CR165","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1002\/(SICI)1097-4547(19970401)48:1<53::AID-JNR5>3.0.CO;2-D","volume":"48","author":"H Riol","year":"1997","unstructured":"Riol H, Tardy M, Rolland B, L\u00e9vesque G, Murthy MR (1997) Detection of the peripheral nervous system (PNS)-type glial fibrillary acidic protein (GFAP) and its mRNA in human lymphocytes. J Neurosci Res 48(1):53\u201362. https:\/\/doi.org\/10.1002\/(SICI)1097-4547(19970401)48:1%3c53::AID-JNR5%3e3.0.CO;2-D","journal-title":"J Neurosci Res"},{"issue":"33","key":"5219_CR166","doi-asserted-by":"publisher","first-page":"29983","DOI":"10.1074\/jbc.M112121200","volume":"277","author":"AL Nielsen","year":"2002","unstructured":"Nielsen AL, Holm IE, Johansen M et al (2002) A new splice variant of glial fibrillary acidic protein, GFAP epsilon, interacts with the presenilin proteins. J Biol Chem 277(33):29983\u201329991. https:\/\/doi.org\/10.1074\/jbc.M112121200","journal-title":"J Biol Chem"},{"issue":"6","key":"5219_CR167","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1111\/jnc.12742","volume":"130","author":"T Clairembault","year":"2014","unstructured":"Clairembault T, Kamphuis W, Leclair-Visonneau L et al (2014) Enteric GFAP expression and phosphorylation in Parkinson\u2019s disease. J Neurochem 130(6):805\u2013815. https:\/\/doi.org\/10.1111\/jnc.12742","journal-title":"J Neurochem"},{"key":"5219_CR168","doi-asserted-by":"publisher","DOI":"10.1177\/1759091420949680","volume":"12","author":"A Messing","year":"2020","unstructured":"Messing A, Brenner M (2020) GFAP at 50. ASN Neuro 12:1759091420949680. https:\/\/doi.org\/10.1177\/1759091420949680","journal-title":"ASN Neuro"},{"issue":"3","key":"5219_CR169","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1046\/j.1471-4159.2001.00595.x","volume":"79","author":"EA Lepekhin","year":"2001","unstructured":"Lepekhin EA, Eliasson C, Berthold C-H et al (2001) Intermediate filaments regulate astrocyte motility. J Neurochem 79(3):617\u2013625. https:\/\/doi.org\/10.1046\/j.1471-4159.2001.00595.x","journal-title":"J Neurochem"},{"issue":"10","key":"5219_CR170","doi-asserted-by":"publisher","first-page":"4521","DOI":"10.1091\/mbc.e08-03-0284","volume":"19","author":"MD Perng","year":"2008","unstructured":"Perng MD, Wen SF, Gibbon T et al (2008) Glial fibrillary acidic protein filaments can tolerate the incorporation of assembly-compromised GFAP-delta, but with consequences for filament organization and alphaB-crystallin association. Mol Biol Cell 19(10):4521\u20134533. https:\/\/doi.org\/10.1091\/mbc.e08-03-0284","journal-title":"Mol Biol Cell"},{"key":"5219_CR171","doi-asserted-by":"publisher","DOI":"10.1177\/17590914221102065","volume":"14","author":"JV van Asperen","year":"2022","unstructured":"van Asperen JV, Robe P, Hol EM (2022) GFAP alternative splicing and the relevance for disease - a focus on diffuse gliomas. ASN Neuro 14:17590914221102065. https:\/\/doi.org\/10.1177\/17590914221102065","journal-title":"ASN Neuro"},{"issue":"5","key":"5219_CR172","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1111\/j.1440-1827.1998.tb03915.x","volume":"48","author":"S Kato","year":"1998","unstructured":"Kato S, Gondo T, Hoshii Y et al (1998) Confocal observation of senile plaques in Alzheimer\u2019s disease: senile plaque morphology and relationship between senile plaques and astrocytes. Pathol Int 48(5):332\u2013340. https:\/\/doi.org\/10.1111\/j.1440-1827.1998.tb03915.x","journal-title":"Pathol Int"},{"key":"5219_CR173","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.neurobiolaging.2021.02.012","volume":"103","author":"BM Bettcher","year":"2021","unstructured":"Bettcher BM, Olson KE, Carlson NE et al (2021) Astrogliosis and episodic memory in late life: higher GFAP is related to worse memory and white matter microstructure in healthy aging and Alzheimer\u2019s disease. Neurobiol Aging 103:68\u201377. https:\/\/doi.org\/10.1016\/j.neurobiolaging.2021.02.012","journal-title":"Neurobiol Aging"},{"issue":"14","key":"5219_CR174","first-page":"3279","volume":"9","author":"S Weggen","year":"1998","unstructured":"Weggen S, Diehlmann A, Buslei R, Beyreuther K, Bayer TA (1998) Prominent expression of presenilin-1 in senile plaques and reactive astrocytes in Alzheimer\u2019s disease brain. NeuroReport 9(14):3279\u20133283","journal-title":"NeuroReport"},{"issue":"4","key":"5219_CR175","doi-asserted-by":"publisher","first-page":"E476","DOI":"10.1073\/pnas.1618657114","volume":"114","author":"L Sun","year":"2017","unstructured":"Sun L, Zhou R, Yang G, Shi Y (2017) Analysis of 138 pathogenic mutations in presenilin-1 on the in vitro production of A\u03b242 and A\u03b240 peptides by \u03b3-secretase. Proc Natl Acad Sci U S A 114(4):E476-e485. https:\/\/doi.org\/10.1073\/pnas.1618657114","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"5219_CR176","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1590\/s0100-879x1997000300005","volume":"30","author":"R Rodnight","year":"1997","unstructured":"Rodnight R, Gon\u00e7alves CA, Wofchuk ST, Leal R (1997) Control of the phosphorylation of the astrocyte marker glial fibrillary acidic protein (GFAP) in the immature rat hippocampus by glutamate and calcium ions: possible key factor in astrocytic plasticity. Braz J Med Biol Res 30(3):325\u2013338. https:\/\/doi.org\/10.1590\/s0100-879x1997000300005","journal-title":"Braz J Med Biol Res"},{"issue":"3","key":"5219_CR177","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1038\/nrm3753","volume":"15","author":"NT Snider","year":"2014","unstructured":"Snider NT, Omary MB (2014) Post-translational modifications of intermediate filament proteins: mechanisms and functions. Nat Rev Mol Cell Biol 15(3):163\u2013177. https:\/\/doi.org\/10.1038\/nrm3753","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"11","key":"5219_CR178","doi-asserted-by":"publisher","first-page":"2364","DOI":"10.1007\/s11064-012-0774-5","volume":"37","author":"SM Sullivan","year":"2012","unstructured":"Sullivan SM, Sullivan RK, Miller SM et al (2012) Phosphorylation of GFAP is associated with injury in the neonatal pig hypoxic-ischemic brain. Neurochem Res 37(11):2364\u20132378. https:\/\/doi.org\/10.1007\/s11064-012-0774-5","journal-title":"Neurochem Res"},{"issue":"12","key":"5219_CR179","doi-asserted-by":"publisher","first-page":"6368","DOI":"10.1021\/pr100666c","volume":"9","author":"JH Herskowitz","year":"2010","unstructured":"Herskowitz JH, Seyfried NT, Duong DM et al (2010) Phosphoproteomic analysis reveals site-specific changes in GFAP and NDRG2 phosphorylation in frontotemporal lobar degeneration. J Proteome Res 9(12):6368\u20136379. https:\/\/doi.org\/10.1021\/pr100666c","journal-title":"J Proteome Res"},{"issue":"11","key":"5219_CR180","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1002\/jnr.23620","volume":"93","author":"A Ishigami","year":"2015","unstructured":"Ishigami A, Masutomi H, Handa S et al (2015) Mass spectrometric identification of citrullination sites and immunohistochemical detection of citrullinated glial fibrillary acidic protein in Alzheimer\u2019s disease brains. J Neurosci Res 93(11):1664\u20131674. https:\/\/doi.org\/10.1002\/jnr.23620","journal-title":"J Neurosci Res"},{"issue":"1","key":"5219_CR181","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1002\/jnr.20431","volume":"80","author":"A Ishigami","year":"2005","unstructured":"Ishigami A, Ohsawa T, Hiratsuka M et al (2005) Abnormal accumulation of citrullinated proteins catalyzed by peptidylarginine deiminase in hippocampal extracts from patients with Alzheimer\u2019s disease. J Neurosci Res 80(1):120\u2013128. https:\/\/doi.org\/10.1002\/jnr.20431","journal-title":"J Neurosci Res"},{"issue":"3","key":"5219_CR182","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1111\/j.1750-3639.1994.tb00839.x","volume":"4","author":"M Inagaki","year":"1994","unstructured":"Inagaki M, Nakamura Y, Takeda M, Nishimura T, Inagaki N (1994) Glial fibrillary acidic protein: dynamic property and regulation by phosphorylation. Brain Pathol 4(3):239\u2013243. https:\/\/doi.org\/10.1111\/j.1750-3639.1994.tb00839.x","journal-title":"Brain Pathol"},{"issue":"7","key":"5219_CR183","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14071354","volume":"14","author":"A Ganne","year":"2022","unstructured":"Ganne A, Balasubramaniam M, Griffin WST, Shmookler Reis RJ, Ayyadevara S (2022) Glial fibrillary acidic protein: a biomarker and drug target for Alzheimer\u2019s disease. Pharmaceutics 14(7):1354. https:\/\/doi.org\/10.3390\/pharmaceutics14071354","journal-title":"Pharmaceutics"},{"issue":"17","key":"5219_CR184","doi-asserted-by":"publisher","first-page":"2682","DOI":"10.1002\/pmic.201300064","volume":"13","author":"Z Jin","year":"2013","unstructured":"Jin Z, Fu Z, Yang J et al (2013) Identification and characterization of citrulline-modified brain proteins by combining HCD and CID fragmentation. Proteomics 13(17):2682\u20132691. https:\/\/doi.org\/10.1002\/pmic.201300064","journal-title":"Proteomics"},{"key":"5219_CR185","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00540","volume":"10","author":"W Faigle","year":"2019","unstructured":"Faigle W, Cruciani C, Wolski W et al (2019) Brain citrullination patterns and T cell reactivity of cerebrospinal fluid-derived CD4(+) T cells in multiple sclerosis. Front Immunol 10:540. https:\/\/doi.org\/10.3389\/fimmu.2019.00540","journal-title":"Front Immunol"},{"issue":"1","key":"5219_CR186","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1002\/cne.20102","volume":"473","author":"AP Nicholas","year":"2004","unstructured":"Nicholas AP, Sambandam T, Echols JD, Tourtellotte WW (2004) Increased citrullinated glial fibrillary acidic protein in secondary progressive multiple sclerosis. J Comp Neurol 473(1):128\u2013136. https:\/\/doi.org\/10.1002\/cne.20102","journal-title":"J Comp Neurol"},{"issue":"8","key":"5219_CR187","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0201744","volume":"13","author":"SE Kim","year":"2018","unstructured":"Kim SE, Park JW, Kim MJ et al (2018) Accumulation of citrullinated glial fibrillary acidic protein in a mouse model of bile duct ligation-induced hepatic fibrosis. PLoS ONE 13(8):e0201744. https:\/\/doi.org\/10.1371\/journal.pone.0201744","journal-title":"PLoS ONE"},{"issue":"10","key":"5219_CR188","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1016\/j.bbapap.2016.06.007","volume":"1864","author":"A Drazic","year":"2016","unstructured":"Drazic A, Myklebust LM, Ree R, Arnesen T (2016) The world of protein acetylation. Biochim Biophys Acta 1864(10):1372\u20131401. https:\/\/doi.org\/10.1016\/j.bbapap.2016.06.007","journal-title":"Biochim Biophys Acta"},{"issue":"Pt 20","key":"5219_CR189","doi-asserted-by":"publisher","first-page":"4368","DOI":"10.1242\/jcs.145912","volume":"127","author":"R Kanski","year":"2014","unstructured":"Kanski R, Sneeboer MA, van Bodegraven EJ et al (2014) Histone acetylation in astrocytes suppresses GFAP and stimulates a reorganization of the intermediate filament network. J Cell Sci 127(Pt 20):4368\u20134380. https:\/\/doi.org\/10.1242\/jcs.145912","journal-title":"J Cell Sci"},{"issue":"12","key":"5219_CR190","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0080779","volume":"8","author":"D Liu","year":"2013","unstructured":"Liu D, Liu C, Li J et al (2013) Proteomic analysis reveals differentially regulated protein acetylation in human amyotrophic lateral sclerosis spinal cord. PLoS ONE 8(12):e80779. https:\/\/doi.org\/10.1371\/journal.pone.0080779","journal-title":"PLoS ONE"},{"issue":"1","key":"5219_CR191","doi-asserted-by":"publisher","DOI":"10.1111\/jnc.16226","volume":"169","author":"D Gogishvili","year":"2025","unstructured":"Gogishvili D, Honey MIJ, Verberk IMW et al (2025) The GFAP proteoform puzzle: how to advance GFAP as a fluid biomarker in neurological diseases. J Neurochem 169(1):e16226. https:\/\/doi.org\/10.1111\/jnc.16226","journal-title":"J Neurochem"},{"issue":"1\u20132","key":"5219_CR192","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.jneumeth.2007.01.001","volume":"162","author":"F Tramontina","year":"2007","unstructured":"Tramontina F, Leite MC, Cereser K et al (2007) Immunoassay for glial fibrillary acidic protein: antigen recognition is affected by its phosphorylation state. J Neurosci Methods 162(1\u20132):282\u2013286. https:\/\/doi.org\/10.1016\/j.jneumeth.2007.01.001","journal-title":"J Neurosci Methods"},{"issue":"16","key":"5219_CR193","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23168960","volume":"23","author":"Z Yang","year":"2022","unstructured":"Yang Z, Arja RD, Zhu T et al (2022) Characterization of calpain and caspase-6-generated glial fibrillary acidic protein breakdown products following traumatic brain injury and astroglial cell injury. Int J Mol Sci 23(16):8960. https:\/\/doi.org\/10.3390\/ijms23168960","journal-title":"Int J Mol Sci"},{"issue":"3","key":"5219_CR194","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0092698","volume":"9","author":"Z Zhang","year":"2014","unstructured":"Zhang Z, Zoltewicz JS, Mondello S et al (2014) Human traumatic brain injury induces autoantibody response against glial fibrillary acidic protein and its breakdown products. PLoS ONE 9(3):e92698. https:\/\/doi.org\/10.1371\/journal.pone.0092698","journal-title":"PLoS ONE"},{"key":"5219_CR195","doi-asserted-by":"publisher","first-page":"71","DOI":"10.4137\/bmi.S9873","volume":"7","author":"JS Zoltewicz","year":"2012","unstructured":"Zoltewicz JS, Scharf D, Yang B et al (2012) Characterization of antibodies that detect human GFAP after traumatic brain injury. Biomark insights 7:71\u201379. https:\/\/doi.org\/10.4137\/bmi.S9873","journal-title":"Biomark insights"},{"issue":"3","key":"5219_CR196","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1016\/j.nbd.2005.05.021","volume":"20","author":"MA Korolainen","year":"2005","unstructured":"Korolainen MA, Auriola S, Nyman TA, Alafuzoff I, Pirttil\u00e4 T (2005) Proteomic analysis of glial fibrillary acidic protein in Alzheimer\u2019s disease and aging brain. Neurobiol Dis 20(3):858\u2013870. https:\/\/doi.org\/10.1016\/j.nbd.2005.05.021","journal-title":"Neurobiol Dis"},{"issue":"8","key":"5219_CR197","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1002\/pmic.200300456","volume":"3","author":"R Porchet","year":"2003","unstructured":"Porchet R, Probst A, Bouras C et al (2003) Analysis of glial acidic fibrillary protein in the human entorhinal cortex during aging and in Alzheimer\u2019s disease. Proteomics 3(8):1476\u20131485. https:\/\/doi.org\/10.1002\/pmic.200300456","journal-title":"Proteomics"},{"issue":"2","key":"5219_CR198","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1023\/a:1022476724381","volume":"23","author":"K Fujita","year":"1998","unstructured":"Fujita K, Kato T, Yamauchi M et al (1998) Increases in fragmented glial fibrillary acidic protein levels in the spinal cords of patients with amyotrophic lateral sclerosis. Neurochem Res 23(2):169\u2013174. https:\/\/doi.org\/10.1023\/a:1022476724381","journal-title":"Neurochem Res"},{"issue":"24","key":"5219_CR199","doi-asserted-by":"publisher","first-page":"3786","DOI":"10.1002\/elps.201200326","volume":"33","author":"JD Guingab-Cagmat","year":"2012","unstructured":"Guingab-Cagmat JD, Newsom K, Vakulenko A et al (2012) In vitro MS-based proteomic analysis and absolute quantification of neuronal-glial injury biomarkers in cell culture system. Electrophoresis 33(24):3786\u20133797. https:\/\/doi.org\/10.1002\/elps.201200326","journal-title":"Electrophoresis"},{"issue":"2","key":"5219_CR200","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/s0006-8993(00)02180-6","volume":"864","author":"YB Lee","year":"2000","unstructured":"Lee YB, Du S, Rhim H et al (2000) Rapid increase in immunoreactivity to GFAP in astrocytes in vitro induced by acidic pH is mediated by calcium influx and calpain I. Brain Res 864(2):220\u2013229. https:\/\/doi.org\/10.1016\/s0006-8993(00)02180-6","journal-title":"Brain Res"},{"issue":"13","key":"5219_CR201","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1089\/neu.2012.2762","volume":"30","author":"JS Zoltewicz","year":"2013","unstructured":"Zoltewicz JS, Mondello S, Yang B et al (2013) Biomarkers track damage after graded injury severity in a rat model of penetrating brain injury. J Neurotrauma 30(13):1161\u20131169. https:\/\/doi.org\/10.1089\/neu.2012.2762","journal-title":"J Neurotrauma"},{"issue":"11","key":"5219_CR202","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0224633","volume":"14","author":"DS Jonesco","year":"2019","unstructured":"Jonesco DS, Hassager C, Frydland M et al (2019) A caspase-6-cleaved fragment of glial fibrillary acidic protein as a potential serological biomarker of CNS injury after cardiac arrest. PLoS ONE 14(11):e0224633. https:\/\/doi.org\/10.1371\/journal.pone.0224633","journal-title":"PLoS ONE"},{"issue":"5","key":"5219_CR203","doi-asserted-by":"publisher","DOI":"10.1042\/an20130032","volume":"5","author":"MH Chen","year":"2013","unstructured":"Chen MH, Hagemann TL, Quinlan RA, Messing A, Perng MD (2013) Caspase cleavage of GFAP produces an assembly-compromised proteolytic fragment that promotes filament aggregation. ASN Neuro 5(5):e00125. https:\/\/doi.org\/10.1042\/an20130032","journal-title":"ASN Neuro"},{"issue":"3","key":"5219_CR204","doi-asserted-by":"publisher","first-page":"936","DOI":"10.2353\/ajpath.2006.050798","volume":"168","author":"PE Mouser","year":"2006","unstructured":"Mouser PE, Head E, Ha KH, Rohn TT (2006) Caspase-mediated cleavage of glial fibrillary acidic protein within degenerating astrocytes of the Alzheimer\u2019s disease brain. Am J Pathol 168(3):936\u2013946. https:\/\/doi.org\/10.2353\/ajpath.2006.050798","journal-title":"Am J Pathol"},{"issue":"11","key":"5219_CR205","doi-asserted-by":"publisher","first-page":"3505","DOI":"10.1093\/brain\/awab223","volume":"144","author":"JB Pereira","year":"2021","unstructured":"Pereira JB, Janelidze S, Smith R et al (2021) Plasma GFAP is an early marker of amyloid-\u03b2 but not tau pathology in Alzheimer\u2019s disease. Brain 144(11):3505\u20133516. https:\/\/doi.org\/10.1093\/brain\/awab223","journal-title":"Brain"},{"issue":"1","key":"5219_CR206","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/s13195-022-01051-2","volume":"14","author":"S Prins","year":"2022","unstructured":"Prins S, de Kam ML, Teunissen CE, Groeneveld GJ (2022) Inflammatory plasma biomarkers in subjects with preclinical Alzheimer\u2019s disease. Alzheimer\u2019s Res Ther 14(1):106. https:\/\/doi.org\/10.1186\/s13195-022-01051-2","journal-title":"Alzheimer's Res Ther"},{"issue":"1","key":"5219_CR207","doi-asserted-by":"publisher","first-page":"265","DOI":"10.3233\/jad-200755","volume":"78","author":"BM Asken","year":"2020","unstructured":"Asken BM, Elahi FM, La Joie R et al (2020) Plasma glial fibrillary acidic protein levels differ along the spectra of amyloid burden and clinical disease stage. J Alzheimers Dis 78(1):265\u2013276. https:\/\/doi.org\/10.3233\/jad-200755","journal-title":"J Alzheimers Dis"},{"issue":"12","key":"5219_CR208","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1001\/jamaneurol.2021.3671","volume":"78","author":"AL Benedet","year":"2021","unstructured":"Benedet AL, Mil\u00e0-Alom\u00e0 M, Vrillon A et al (2021) Differences between plasma and cerebrospinal fluid glial fibrillary acidic protein levels across the Alzheimer disease continuum. JAMA Neurol 78(12):1471\u20131483. https:\/\/doi.org\/10.1001\/jamaneurol.2021.3671","journal-title":"JAMA Neurol"},{"issue":"1","key":"5219_CR209","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s13195-021-00804-9","volume":"13","author":"C Cicognola","year":"2021","unstructured":"Cicognola C, Janelidze S, Hertze J et al (2021) Plasma glial fibrillary acidic protein detects Alzheimer pathology and predicts future conversion to Alzheimer dementia in patients with mild cognitive impairment. Alzheimers Res Ther 13(1):68. https:\/\/doi.org\/10.1186\/s13195-021-00804-9","journal-title":"Alzheimers Res Ther"},{"key":"5219_CR210","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2022.887498","volume":"14","author":"T Parvizi","year":"2022","unstructured":"Parvizi T, K\u00f6nig T, Wurm R et al (2022) Real-world applicability of glial fibrillary acidic protein and neurofilament light chain in Alzheimer\u2019s disease. Front Aging Neurosci 14:887498. https:\/\/doi.org\/10.3389\/fnagi.2022.887498","journal-title":"Front Aging Neurosci"},{"issue":"2","key":"5219_CR211","doi-asserted-by":"publisher","first-page":"481","DOI":"10.3233\/jad-180325","volume":"67","author":"P Oeckl","year":"2019","unstructured":"Oeckl P, Halbgebauer S, Anderl-Straub S et al (2019) Glial fibrillary acidic protein in serum is increased in Alzheimer\u2019s disease and correlates with cognitive impairment. J Alzheimers Dis 67(2):481\u2013488. https:\/\/doi.org\/10.3233\/jad-180325","journal-title":"J Alzheimers Dis"},{"issue":"6","key":"5219_CR212","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1017\/s1355617721000813","volume":"28","author":"BM Asken","year":"2022","unstructured":"Asken BM, VandeVrede L, Rojas JC et al (2022) Lower white matter volume and worse executive functioning reflected in higher levels of plasma GFAP among older adults with and without cognitive impairment. J Int Neuropsychol Soc 28(6):588\u2013599. https:\/\/doi.org\/10.1017\/s1355617721000813","journal-title":"J Int Neuropsychol Soc"},{"key":"5219_CR213","doi-asserted-by":"publisher","unstructured":"Varma VR, An Y, Kac PR et al (2025) Longitudinal progression of blood biomarkers reveals a key role of reactive astrocytosis in preclinical Alzheimer\u2019s disease. Med 100724. https:\/\/doi.org\/10.1016\/j.medj.2025.100724","DOI":"10.1016\/j.medj.2025.100724"},{"issue":"5","key":"5219_CR214","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.8903","volume":"8","author":"TKS Ng","year":"2025","unstructured":"Ng TKS, Beck T, Boyle P et al (2025) APOE4, blood neurodegenerative biomarkers, and cognitive decline in community-dwelling older adults. JAMA Netw Open 8(5):e258903. https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.8903","journal-title":"JAMA Netw Open"},{"issue":"1","key":"5219_CR215","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s00401-024-02828-5","volume":"148","author":"JM Phillips","year":"2024","unstructured":"Phillips JM, Winfree RL, Seto M et al (2024) Pathologic and clinical correlates of region-specific brain GFAP in Alzheimer\u2019s disease. Acta Neuropathol 148(1):69. https:\/\/doi.org\/10.1007\/s00401-024-02828-5","journal-title":"Acta Neuropathol"},{"key":"5219_CR216","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.pneurobio.2016.01.001","volume":"144","author":"LM Osborn","year":"2016","unstructured":"Osborn LM, Kamphuis W, Wadman WJ, Hol EM (2016) Astrogliosis: an integral player in the pathogenesis of Alzheimer\u2019s disease. Prog Neurobiol 144:121\u2013141. https:\/\/doi.org\/10.1016\/j.pneurobio.2016.01.001","journal-title":"Prog Neurobiol"},{"issue":"6","key":"5219_CR217","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1002\/ana.25874","volume":"88","author":"KB Rajan","year":"2020","unstructured":"Rajan KB, Aggarwal NT, McAninch EA et al (2020) Remote blood biomarkers of longitudinal cognitive outcomes in a population study. Ann Neurol 88(6):1065\u20131076. https:\/\/doi.org\/10.1002\/ana.25874","journal-title":"Ann Neurol"},{"key":"5219_CR218","doi-asserted-by":"publisher","unstructured":"Abbas S, Ferreira PCL, Bellaver B et al (2025) Utility of plasma GFAP as a secondary endpoint for clinical trials in Alzheimer\u2019s disease. J Prev Alzheimers Dis, p 100205. https:\/\/doi.org\/10.1016\/j.tjpad.2025.100205","DOI":"10.1016\/j.tjpad.2025.100205"},{"issue":"9","key":"5219_CR219","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10091907","volume":"10","author":"JA Hendrix","year":"2021","unstructured":"Hendrix JA, Airey DC, Britton A et al (2021) Cross-sectional exploration of plasma biomarkers of Alzheimer\u2019s disease in down syndrome: early data from the longitudinal investigation for enhancing down syndrome research (LIFE-DSR) study. J Clin Med 10(9):1907. https:\/\/doi.org\/10.3390\/jcm10091907","journal-title":"J Clin Med"},{"issue":"10","key":"5219_CR220","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1002\/acn3.51652","volume":"9","author":"MM Gonzales","year":"2022","unstructured":"Gonzales MM, Wiedner C, Wang CP et al (2022) A population-based meta-analysis of circulating GFAP for cognition and dementia risk. Ann Clin Transl Neurol 9(10):1574\u20131585. https:\/\/doi.org\/10.1002\/acn3.51652","journal-title":"Ann Clin Transl Neurol"},{"issue":"1","key":"5219_CR221","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1038\/s41398-023-02558-4","volume":"13","author":"M Bucci","year":"2023","unstructured":"Bucci M, Bluma M, Savitcheva I et al (2023) Profiling of plasma biomarkers in the context of memory assessment in a tertiary memory clinic. Transl Psychiatry 13(1):268. https:\/\/doi.org\/10.1038\/s41398-023-02558-4","journal-title":"Transl Psychiatry"},{"issue":"1","key":"5219_CR222","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1186\/s13195-022-01093-6","volume":"14","author":"S Baiardi","year":"2022","unstructured":"Baiardi S, Quadalti C, Mammana A et al (2022) Diagnostic value of plasma p-tau181, NfL, and GFAP in a clinical setting cohort of prevalent neurodegenerative dementias. Alzheimers Res Ther 14(1):153. https:\/\/doi.org\/10.1186\/s13195-022-01093-6","journal-title":"Alzheimers Res Ther"},{"issue":"10","key":"5219_CR223","doi-asserted-by":"publisher","first-page":"1988","DOI":"10.1002\/alz.12806","volume":"18","author":"J Simr\u00e9n","year":"2022","unstructured":"Simr\u00e9n J, Weninger H, Brum WS et al (2022) Differences between blood and cerebrospinal fluid glial fibrillary acidic protein levels: the effect of sample stability. Alzheimers Dement 18(10):1988\u20131992. https:\/\/doi.org\/10.1002\/alz.12806","journal-title":"Alzheimers Dement"},{"issue":"1","key":"5219_CR224","doi-asserted-by":"publisher","first-page":"e12168","DOI":"10.1002\/dad2.12168","volume":"13","author":"NJ Ashton","year":"2021","unstructured":"Ashton NJ, Su\u00e1rez-Calvet M, Karikari TK et al (2021) Effects of pre-analytical procedures on blood biomarkers for Alzheimer\u2019s pathophysiology, glial activation, and neurodegeneration. Alzheimers Dement (Amst) 13(1):e12168. https:\/\/doi.org\/10.1002\/dad2.12168","journal-title":"Alzheimers Dement (Amst)"},{"issue":"2","key":"5219_CR225","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1523\/jneurosci.3742-14.2015","volume":"35","author":"BA Plog","year":"2015","unstructured":"Plog BA, Dashnaw ML, Hitomi E et al (2015) Biomarkers of traumatic injury are transported from brain to blood via the glymphatic system. J Neurosci 35(2):518\u2013526. https:\/\/doi.org\/10.1523\/jneurosci.3742-14.2015","journal-title":"J Neurosci"},{"issue":"22","key":"5219_CR226","doi-asserted-by":"publisher","DOI":"10.3390\/ijms242216288","volume":"24","author":"AE Alkhalifa","year":"2023","unstructured":"Alkhalifa AE, Al-Ghraiybah NF, Odum J et al (2023) Blood-brain barrier breakdown in Alzheimer\u2019s disease: mechanisms and targeted strategies. Int J Mol Sci 24(22):16288. https:\/\/doi.org\/10.3390\/ijms242216288","journal-title":"Int J Mol Sci"},{"issue":"3","key":"5219_CR227","doi-asserted-by":"publisher","DOI":"10.1111\/nan.12782","volume":"48","author":"C Kurz","year":"2022","unstructured":"Kurz C, Walker L, Rauchmann BS, Perneczky R (2022) Dysfunction of the blood-brain barrier in Alzheimer\u2019s disease: evidence from human studies. Neuropathol Appl Neurobiol 48(3):e12782. https:\/\/doi.org\/10.1111\/nan.12782","journal-title":"Neuropathol Appl Neurobiol"},{"issue":"4","key":"5219_CR228","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1093\/brain\/awac333","volume":"146","author":"S Janelidze","year":"2023","unstructured":"Janelidze S, Bali D, Ashton NJ et al (2023) Head-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer\u2019s disease. Brain 146(4):1592\u20131601. https:\/\/doi.org\/10.1093\/brain\/awac333","journal-title":"Brain"},{"issue":"11","key":"5219_CR229","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1001\/jamaneurol.2021.3180","volume":"78","author":"S Janelidze","year":"2021","unstructured":"Janelidze S, Teunissen CE, Zetterberg H et al (2021) Head-to-head comparison of 8 plasma amyloid-\u03b2 42\/40 assays in Alzheimer disease. JAMA Neurol 78(11):1375\u20131382. https:\/\/doi.org\/10.1001\/jamaneurol.2021.3180","journal-title":"JAMA Neurol"},{"issue":"1","key":"5219_CR230","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1186\/s13195-022-01113-5","volume":"14","author":"EB Dammer","year":"2022","unstructured":"Dammer EB, Ping L, Duong DM et al (2022) Multi-platform proteomic analysis of Alzheimer\u2019s disease cerebrospinal fluid and plasma reveals network biomarkers associated with proteostasis and the matrisome. Alzheimers Res Ther 14(1):174. https:\/\/doi.org\/10.1186\/s13195-022-01113-5","journal-title":"Alzheimers Res Ther"},{"issue":"1","key":"5219_CR231","doi-asserted-by":"publisher","first-page":"193","DOI":"10.3233\/jad-220399","volume":"89","author":"J Timsina","year":"2022","unstructured":"Timsina J, Gomez-Fonseca D, Wang L et al (2022) Comparative analysis of Alzheimer\u2019s disease cerebrospinal fluid biomarkers measurement by multiplex SOMAscan platform and immunoassay-based approach. J Alzheimers Dis 89(1):193\u2013207. https:\/\/doi.org\/10.3233\/jad-220399","journal-title":"J Alzheimers Dis"},{"issue":"1","key":"5219_CR232","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1038\/s42003-023-05454-1","volume":"6","author":"A Tin","year":"2023","unstructured":"Tin A, Fohner AE, Yang Q et al (2023) Identification of circulating proteins associated with general cognitive function among middle-aged and older adults. Commun Biol 6(1):1117. https:\/\/doi.org\/10.1038\/s42003-023-05454-1","journal-title":"Commun Biol"},{"issue":"1","key":"5219_CR233","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1186\/s40478-019-0795-2","volume":"7","author":"CD Whelan","year":"2019","unstructured":"Whelan CD, Mattsson N, Nagle MW et al (2019) Multiplex proteomics identifies novel CSF and plasma biomarkers of early Alzheimer\u2019s disease. Acta Neuropathol Commun 7(1):169. https:\/\/doi.org\/10.1186\/s40478-019-0795-2","journal-title":"Acta Neuropathol Commun"},{"key":"5219_CR234","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.889647","volume":"13","author":"BC Carlyle","year":"2022","unstructured":"Carlyle BC, Kitchen RR, Mattingly Z et al (2022) Technical performance evaluation of Olink proximity extension assay for blood-based biomarker discovery in longitudinal studies of Alzheimer\u2019s disease. Front Neurol 13:889647. https:\/\/doi.org\/10.3389\/fneur.2022.889647","journal-title":"Front Neurol"},{"issue":"1","key":"5219_CR235","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s13024-024-00753-5","volume":"19","author":"X Zeng","year":"2024","unstructured":"Zeng X, Lafferty TK, Sehrawat A et al (2024) Multi-analyte proteomic analysis identifies blood-based neuroinflammation, cerebrovascular and synaptic biomarkers in preclinical Alzheimer\u2019s disease. Mol Neurodegener 19(1):68. https:\/\/doi.org\/10.1186\/s13024-024-00753-5","journal-title":"Mol Neurodegener"},{"key":"5219_CR236","doi-asserted-by":"publisher","DOI":"10.21203\/rs.3.rs-3725688\/v1","author":"J Arranz","year":"2023","unstructured":"Arranz J, Zhu N, Rubio-Guerra S et al (2023) Diagnostic performance of plasma pTau 217, pTau 181, A\u03b2 1\u201342 and A\u03b2 1\u201340 in the Lumipulse automated platform for the detection of Alzheimer disease. Res Sq. https:\/\/doi.org\/10.21203\/rs.3.rs-3725688\/v1","journal-title":"Res Sq"},{"issue":"1","key":"5219_CR237","doi-asserted-by":"publisher","DOI":"10.1002\/dad2.12545","volume":"16","author":"DJ Figdore","year":"2024","unstructured":"Figdore DJ, Wiste HJ, Bornhorst JA et al (2024) Performance of the lumipulse plasma A\u03b242\/40 and pTau181 immunoassays in the detection of amyloid pathology. Alzheimers Dement (Amst) 16(1):e12545. https:\/\/doi.org\/10.1002\/dad2.12545","journal-title":"Alzheimers Dement (Amst)"},{"issue":"2","key":"5219_CR238","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1093\/brain\/awae368","volume":"148","author":"A Pilotto","year":"2024","unstructured":"Pilotto A, Quaresima V, Trasciatti C et al (2024) Plasma p-tau217 in Alzheimer\u2019s disease: Lumipulse and ALZpath SIMOA head-to-head comparison. Brain 148(2):408\u2013415. https:\/\/doi.org\/10.1093\/brain\/awae368","journal-title":"Brain"},{"issue":"8","key":"5219_CR239","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.jalz.2018.02.013","volume":"14","author":"MM Mielke","year":"2018","unstructured":"Mielke MM, Hagen CE, Xu J et al (2018) Plasma phospho-tau181 increases with Alzheimer\u2019s disease clinical severity and is associated with tau- and amyloid-positron emission tomography. Alzheimers Dement 14(8):989\u2013997. https:\/\/doi.org\/10.1016\/j.jalz.2018.02.013","journal-title":"Alzheimers Dement"},{"key":"5219_CR240","doi-asserted-by":"publisher","unstructured":"Bader JM, Geyer PE, M\u00fcller JB et al (2020) Proteome profiling in cerebrospinal fluid reveals novel biomarkers of Alzheimer\u2019s disease. Mol Syst Biol 16(6):e9356. https:\/\/doi.org\/10.15252\/msb.20199356","DOI":"10.15252\/msb.20199356"},{"issue":"2","key":"5219_CR241","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.0000000000210225","volume":"104","author":"A Soldan","year":"2025","unstructured":"Soldan A, Pettigrew C, Wang J et al (2025) Blood-based biomarkers and risk of onset of mild cognitive impairment over the short and long term. Neurology 104(2):e210225. https:\/\/doi.org\/10.1212\/wnl.0000000000210225","journal-title":"Neurology"},{"issue":"2","key":"5219_CR242","doi-asserted-by":"publisher","DOI":"10.1002\/alz.14413","volume":"21","author":"L Ibanez","year":"2025","unstructured":"Ibanez L, Liu M, Beric A et al (2025) Benchmarking of a multi-biomarker low-volume panel for Alzheimer\u2019s disease and related dementia research. Alzheimers Dement 21(2):e14413. https:\/\/doi.org\/10.1002\/alz.14413","journal-title":"Alzheimers Dement"},{"issue":"5","key":"5219_CR243","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/0197-4580(93)90100-p","volume":"14","author":"NR Nichols","year":"1993","unstructured":"Nichols NR, Day JR, Laping NJ, Johnson SA, Finch CE (1993) GFAP mRNA increases with age in rat and human brain. Neurobiol Aging 14(5):421\u2013429. https:\/\/doi.org\/10.1016\/0197-4580(93)90100-p","journal-title":"Neurobiol Aging"},{"issue":"S15","key":"5219_CR244","doi-asserted-by":"publisher","DOI":"10.1002\/alz.076402","volume":"19","author":"S Abbas","year":"2023","unstructured":"Abbas S, Bellaver B, Ferreira PCL et al (2023) Sex impacts the association of plasma glial fibrillary acidic protein with neurodegeneration in Alzheimer\u2019s disease. Alzheimers Dement 19(S15):e076402. https:\/\/doi.org\/10.1002\/alz.076402","journal-title":"Alzheimers Dement"},{"issue":"1","key":"5219_CR245","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s13195-025-01684-z","volume":"17","author":"C Boccalini","year":"2025","unstructured":"Boccalini C, Peretti DE, Scheffler M et al (2025) Sex differences in the association of Alzheimer\u2019s disease biomarkers and cognition in a multicenter memory clinic study. Alzheimers Res Ther 17(1):46. https:\/\/doi.org\/10.1186\/s13195-025-01684-z","journal-title":"Alzheimers Res Ther"},{"issue":"8","key":"5219_CR246","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1038\/mp.2012.107","volume":"18","author":"BM Brown","year":"2013","unstructured":"Brown BM, Peiffer JJ, Taddei K et al (2013) Physical activity and amyloid-\u03b2 plasma and brain levels: results from the Australian imaging, biomarkers and lifestyle study of ageing. Mol Psychiatry 18(8):875\u2013881. https:\/\/doi.org\/10.1038\/mp.2012.107","journal-title":"Mol Psychiatry"},{"key":"5219_CR247","unstructured":"Gauthier S WC, Servaes S, Morais JA, Rosa-Neto P (2022) World Alzheimer Report 2022: Life after diagnosis: Navigating treatment, care and support. Alzheimer\u2019s Dis Int. https:\/\/www.alzint.org\/resource\/world-alzheimer-report-2022\/. Accessed 10 May 2024"},{"issue":"10","key":"5219_CR248","doi-asserted-by":"publisher","first-page":"e164","DOI":"10.1038\/tp.2012.91","volume":"2","author":"S Gardener","year":"2012","unstructured":"Gardener S, Gu Y, Rainey-Smith SR et al (2012) Adherence to a Mediterranean diet and Alzheimer\u2019s disease risk in an Australian population. Transl Psychiatry 2(10):e164\u2013e164. https:\/\/doi.org\/10.1038\/tp.2012.91","journal-title":"Transl Psychiatry"},{"key":"5219_CR249","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbr.2022.114108","volume":"437","author":"KR Sewell","year":"2023","unstructured":"Sewell KR, Rainey-Smith SR, Villemagne VL et al (2023) The interaction between physical activity and sleep on cognitive function and brain beta-amyloid in older adults. Behav Brain Res 437:114108. https:\/\/doi.org\/10.1016\/j.bbr.2022.114108","journal-title":"Behav Brain Res"},{"issue":"5","key":"5219_CR250","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.5665\/sleep.5756","volume":"39","author":"BM Brown","year":"2016","unstructured":"Brown BM, Rainey-Smith SR, Villemagne VL et al (2016) The relationship between sleep quality and brain amyloid burden. Sleep 39(5):1063\u20131068. https:\/\/doi.org\/10.5665\/sleep.5756","journal-title":"Sleep"},{"issue":"1","key":"5219_CR251","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1038\/s41398-018-0293-5","volume":"8","author":"SR Rainey-Smith","year":"2018","unstructured":"Rainey-Smith SR, Gu Y, Gardener SL et al (2018) Mediterranean diet adherence and rate of cerebral A\u03b2-amyloid accumulation: data from the Australian imaging, biomarkers and lifestyle study of Ageing. Transl Psychiatry 8(1):238. https:\/\/doi.org\/10.1038\/s41398-018-0293-5","journal-title":"Transl Psychiatry"},{"issue":"2","key":"5219_CR252","doi-asserted-by":"publisher","first-page":"154","DOI":"10.3945\/an.114.007617","volume":"6","author":"O van de Rest","year":"2015","unstructured":"van de Rest O, Berendsen AA, Haveman-Nies A, de Groot LC (2015) Dietary patterns, cognitive decline, and dementia: a systematic review. Adv Nutr 6(2):154\u2013168. https:\/\/doi.org\/10.3945\/an.114.007617","journal-title":"Adv Nutr"},{"key":"5219_CR253","doi-asserted-by":"publisher","first-page":"25","DOI":"10.14283\/jarlife.2023.7","volume":"12","author":"KV Giudici","year":"2023","unstructured":"Giudici KV, de Souto Barreto P, Guyonnet S et al (2023) Effect of a 1-year nutritional blend supplementation on plasma p-tau181 and GFAP levels among community-dwelling older adults: a secondary analysis of the Nolan trial. JAR Life 12:25\u201334. https:\/\/doi.org\/10.14283\/jarlife.2023.7","journal-title":"JAR Life"},{"issue":"S14","key":"5219_CR254","doi-asserted-by":"publisher","DOI":"10.1002\/alz.080051","volume":"19","author":"DA Dempsey","year":"2023","unstructured":"Dempsey DA, Deardorff R, Apostolova LG et al (2023) Mediterranean diet foods are associated with plasma biomarkers of Alzheimer\u2019s disease and related dementias. Alzheimers Dement 19(S14):e080051. https:\/\/doi.org\/10.1002\/alz.080051","journal-title":"Alzheimers Dement"},{"issue":"1","key":"5219_CR255","doi-asserted-by":"publisher","first-page":"21702","DOI":"10.1038\/s41598-024-72806-0","volume":"14","author":"J Nilsson","year":"2024","unstructured":"Nilsson J, Jiang Y, Johannesson M et al (2024) Plasma markers of neurodegeneration, latent cognitive abilities and physical activity in healthy aging. Sci Rep 14(1):21702. https:\/\/doi.org\/10.1038\/s41598-024-72806-0","journal-title":"Sci Rep"},{"issue":"6","key":"5219_CR256","doi-asserted-by":"publisher","first-page":"5911","DOI":"10.1007\/s11357-024-01130-2","volume":"46","author":"KR Sewell","year":"2024","unstructured":"Sewell KR, Rainey-Smith SR, Pedrini S et al (2024) The impact of exercise on blood-based biomarkers of Alzheimer\u2019s disease in cognitively unimpaired older adults. Geroscience 46(6):5911\u20135923. https:\/\/doi.org\/10.1007\/s11357-024-01130-2","journal-title":"Geroscience"},{"issue":"4","key":"5219_CR257","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1080\/13825585.2018.1513449","volume":"26","author":"L Fine","year":"2019","unstructured":"Fine L, Weinborn M, Ng A et al (2019) Sleep disruption explains age-related prospective memory deficits: implications for cognitive aging and intervention. Aging Neuropsychol Cogn 26(4):621\u2013636. https:\/\/doi.org\/10.1080\/13825585.2018.1513449","journal-title":"Aging Neuropsychol Cogn"},{"issue":"21","key":"5219_CR258","doi-asserted-by":"publisher","first-page":"5263","DOI":"10.1523\/jneurosci.3981-16.2017","volume":"37","author":"M Bellesi","year":"2017","unstructured":"Bellesi M, de Vivo L, Chini M et al (2017) Sleep loss promotes astrocytic phagocytosis and microglial activation in mouse cerebral cortex. J Neurosci 37(21):5263\u20135273. https:\/\/doi.org\/10.1523\/jneurosci.3981-16.2017","journal-title":"J Neurosci"},{"key":"5219_CR259","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s12915-015-0176-7","volume":"13","author":"M Bellesi","year":"2015","unstructured":"Bellesi M, de Vivo L, Tononi G, Cirelli C (2015) Effects of sleep and wake on astrocytes: clues from molecular and ultrastructural studies. BMC Biol 13:66. https:\/\/doi.org\/10.1186\/s12915-015-0176-7","journal-title":"BMC Biol"},{"issue":"2","key":"5219_CR260","doi-asserted-by":"publisher","DOI":"10.1111\/cns.14558","volume":"30","author":"X Yu","year":"2024","unstructured":"Yu X, Zhou X, He Z et al (2024) Sleep and APOE-\u03b54 have a synergistic effect on plasma biomarkers and longitudinal cognitive decline in older adults. CNS Neurosci Ther 30(2):e14558. https:\/\/doi.org\/10.1111\/cns.14558","journal-title":"CNS Neurosci Ther"},{"issue":"2","key":"5219_CR261","doi-asserted-by":"publisher","first-page":"e12439","DOI":"10.1002\/dad2.12439","volume":"15","author":"AL Sunde","year":"2023","unstructured":"Sunde AL, Alsnes IV, Aarsland D et al (2023) Preanalytical stability of plasma biomarkers for Alzheimer\u2019s disease pathology. Alzheimer\u2019s Dement (Amst) 15(2):e12439. https:\/\/doi.org\/10.1002\/dad2.12439","journal-title":"Alzheimer's Dement (Amst)"},{"issue":"2","key":"5219_CR262","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1002\/alz.13518","volume":"20","author":"WS Brum","year":"2024","unstructured":"Brum WS, Ashton NJ, Simr\u00e9n J et al (2024) Biological variation estimates of Alzheimer\u2019s disease plasma biomarkers in healthy individuals. Alzheimers Dement 20(2):1284\u20131297. https:\/\/doi.org\/10.1002\/alz.13518","journal-title":"Alzheimers Dement"},{"issue":"12","key":"5219_CR263","doi-asserted-by":"publisher","first-page":"5531","DOI":"10.1002\/alz.13163","volume":"19","author":"H Huber","year":"2023","unstructured":"Huber H, Ashton NJ, Schieren A et al (2023) Levels of Alzheimer\u2019s disease blood biomarkers are altered after food intake\u2014a pilot intervention study in healthy adults. Alzheimers Dement 19(12):5531\u20135540. https:\/\/doi.org\/10.1002\/alz.13163","journal-title":"Alzheimers Dement"},{"issue":"6","key":"5219_CR264","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1038\/nbt.1641","volume":"28","author":"DM Rissin","year":"2010","unstructured":"Rissin DM, Kan CW, Campbell TG et al (2010) Single-molecule enzyme-linked immunosorbent assay detects serum proteins at subfemtomolar concentrations. Nat Biotechnol 28(6):595\u2013599. https:\/\/doi.org\/10.1038\/nbt.1641","journal-title":"Nat Biotechnol"},{"issue":"2","key":"5219_CR265","doi-asserted-by":"publisher","first-page":"495","DOI":"10.3233\/jad-220673","volume":"90","author":"C Xu","year":"2022","unstructured":"Xu C, Zhao L, Dong C (2022) A review of application of A\u03b242\/40 ratio in diagnosis and prognosis of Alzheimer\u2019s disease. J Alzheimers Dis 90(2):495\u2013512. https:\/\/doi.org\/10.3233\/jad-220673","journal-title":"J Alzheimers Dis"},{"issue":"7","key":"5219_CR266","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1038\/s41582-022-00665-2","volume":"18","author":"TK Karikari","year":"2022","unstructured":"Karikari TK, Ashton NJ, Brinkmalm G et al (2022) Blood phospho-tau in Alzheimer disease: analysis, interpretation, and clinical utility. Nat Rev Neurol 18(7):400\u2013418. https:\/\/doi.org\/10.1038\/s41582-022-00665-2","journal-title":"Nat Rev Neurol"}],"container-title":["Molecular Neurobiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-025-05219-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12035-025-05219-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-025-05219-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T11:03:39Z","timestamp":1761908619000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12035-025-05219-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,21]]},"references-count":266,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["5219"],"URL":"https:\/\/doi.org\/10.1007\/s12035-025-05219-3","relation":{},"ISSN":["0893-7648","1559-1182"],"issn-type":[{"value":"0893-7648","type":"print"},{"value":"1559-1182","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,21]]},"assertion":[{"value":"12 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval and Consent to Participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}